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ABSTRACT OF THE DISSERTATION
ROLE OF WITHAFERIN A AS A NEUROPROTECTANT AGAINST BETA AMYLOID
INDUCED TOXICITY AND ASSOCIATED MECHANISM
by
Sneham Tiwari
Florida International University, 2019
Miami, Florida
Professor Madhavan Nair, Major Professor
Neurological disorders are the biggest concern globally and ageing contributes in
worsening the disease scenarios. In AD or AD like diseases, there is abnormal
accumulation of extracellular amyloid beta produced due to abnormal processing of the
transmembrane amyloid precursor protein, by β and γ-secretases. It spreads in the cortical
and limbic regions of the brain leading to neuronal toxicity, impairment in memory and
neurological functions. Aβ deposition in the CNS is common in aging HIV patients.
Neurotoxic protein Tat, results in increased Aβ in combination with drugs of abuse
cocaine. We examined the role of Withaferin A, against Aβ induced neurotoxicity. Our invitro dose optimization study demonstrates that lower concentrations (0.5–2 μM) of WA
significantly reduce the Aβ40, without inducing cytotoxicity in the APP plasmid transfected
SH-SY5Y cells (SHAPP). We demonstrate that Aβ secretion is increased in the presence
of Tat (50 ng/ml) and coc (0.1 μM), WA reduces the Tat and coc induced increase in Aβ40.
Additionally, we studied the role of WA against NF-kB mediated neuroinflammation, and
observed that WA inhibits the expression of NFkB2 and RELA transcription factors, which
play a major role in the expression of inflammatory chemokines. Further, to address the
issue of minimal drug bioavailability in the CNS, we developed the WA loaded liposomal
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nanoformulation (WA-LNF) and characterized its size (499+/-50nm), toxicity and drug
binding efficacy (28%). Our in-vitro 3D BBB transmigration of WA-LNF demonstrated
~40% transmigration efficiency. Furthermore, it was imperative for us to understand the
mechanism of action of WA, therefore we studied the molecular mechanism of interaction
of WA with Aβ protein by in-silico molecular dynamics simulations. We demonstrated that
WA binds to the middle region of Aβ protein and the amino acid motif involved were
FAEDVGS highlighting the mid-region Aβ capture by WA. 3 Hydrogen bonds were formed
between WA and the amino acids, ASN17, GLY15 and SER16. This study reports WA as
a potent neuroprotectant against amyloid induced neurotoxicity. Our study may have an
immense therapeutic potential to target Aβ in the CNS, in the ageing patients and/or
PLWH and/or ageing drug abusers.
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CHAPTER 1: ALZHEIMER ’S DISEASE: PATHOGENESIS, DIAGNOSTICS AND
THERAPEUTICS
Parts of this chapter will appear in the International Journal of Nanomedicine, 2019
(Acknowledgements to Dove Medical Press as the original publisher of the article)

1.1 Introduction
Alzheimer’s Disease (AD) is a neurodegenerative and prominent protein conformational
disorder (PCD) [1, 2] primarily caused by the aberrant processing and polymerization of
normally soluble proteins [3]. The process of protein folding in the cell is tightly regulated,
which encompasses various proteins, proteases, molecular chaperones that play a vital
role in folding and clearance of misfolded protein along with regulation. However, genetic
or sporadic environmental factors can alter this proof reading mechanism compromising
the efficiency of protein folding process and resulting in non-native misfolded,
dysregulated, destabilized, and aggregated proteins. This leads to PCD, in which the
altered protein conformations contribute to cell toxicity, functional insufficiency and
negative regulation. Protein misfolding is responsible for several neurological and
metabolic disorders [2]. Proteins need to be folded into their final active state,
corresponding to a particular conformation and have to be stable in that state for their
proper functioning. A misfolded protein can undergo self- aggregation. Soluble neuronal
proteins when misfolded attain altered conformations due to genetic mutation, external
factors or ageing, and aggregate leading to abnormal neuronal functions and loss [4]. AD’s
discovery as a neurodegenerative disease is attributed to Alois Alzheimer, a German
neurologist, who made first discovery when he examined a 51-year-old woman named
Auguste Deter who was suffering with loss of memory, language issues, disorientation
and hallucinations. Her autopsy revealed plaques and tangles in the cerebral cortex [5],
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which convinced him that this was unusual than typical dementia. His discovery was
followed by further research which disclosed the presence of neuritic Amyloid Beta (Aβ)
plaques in dementia patients [6]. Young onset of the disease is attributed to predisposition
to Presenelin 1 (PS1) genetic mutation, which is rare but a potent cause [7]. Other
neurodegenerative diseases associated with abnormal protein conformations, are
Parkinson’s disease (PD), Creutzfeldt- Jacob disease (CJD), Huntington’s disease (HD),
Machado-Joseph disease (MJD), which are caused due to abnormalities in α-synuclein,
normal and pathological isoforms of prion protein (PrPc and PrPSc), Huntingtin and Ataxin
3 proteins respectively. Here we have focused on understanding factors associated with
AD pathogenesis, mechanisms, state of ART diagnostics and therapeutics available
currently (Figure 1.1).

Figure 1.1 An overview of the fields of research that need to be
elucidated to understand the pathophysiology of AD and therapeutic
strategies to combat AD.
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1.2 AD Pathogenesis
AD is a highly complex and progressive neurodegenerative disease [8]. It is one of the
leading cause of dementia cases globally. In US alone, approximately 5.3 million
Americans have AD, out of which 5.1 million are 65 years or older and 200,000 have
younger onset of AD [9]. Commonly studied histopathological characteristics of AD are
extracellular aggregates of Aβ plaques and intracellular aggregations of neurofibrillary
tangles (NFTs), made of hyperphosphorylated microtubule-associated Tau protein. Aβ
plaques develop initially in the basal, temporal and orbitofrontal neocortex regions of brain
and in later stages progress throughout the neocortex, hippocampus, amygdala,
diencephalon and the basal ganglia. In critical cases, Aβ is found throughout the
mesencephalon, lower brainstem and cerebellar cortex. This concentration of Aβ triggers
Tau tangles formation, in the locus coeruleus, transentorhinal and entorhinal areas of
brain. In critical stage, it spreads to the hippocampus and neocortex [10]. Aβ and NFTs
are the major players in the AD progression.

1.3 Key events in the pathogenesis of AD
The amyloid pathogenesis starts with the altered cleavage of Amyloid Precursor Protein
(APP), an integral protein on the plasma membrane, by β-secretases (BACE-1) and secretases to produce non-soluble Aβ fibrils. Aβ then oligomerizes and diffuses into
synaptic clefts and interferes with the synaptic signaling [11, 12]. Consequently, it
polymerizes into insoluble amyloid fibrils that aggregate into plaques. This polymerization
leads to activation of kinases, which lead to hyperphosphorylation of the microtubuleassociated protein, tau, and its polymerization into insoluble NFTs. The aggregation of
plaques and tangles is followed by microglia recruitment near plaques. This promotes
microglial activation and local inflammatory response and contributes to neurotoxicity.
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1.3.1 Structure and function of amyloid precursor protein
APP belongs to a family of associated proteins including mammalian amyloid precursor
like proteins (APLP1 and APLP2) and amyloid precursor protein-like (APPL) in Drosophila.
It is an integral transmembrane protein with extracellular domains (Figure 1.2). APP, in
diseased state, generates amyloidogenic fragments, by differential cleavage by enzymes
[7]. The physiological functions of APP are still less understood, studies with transiently
transfected cell lines show that APP moderates cell survival, growth and motility, along
neutraneutrnnwith neurite outgrowth and functions, which are attributed to release of
soluble ectodomains upon normal cleavage of APP [13, 14]. The importance of APP has
been highlighted by studies where neuronal abnormalities have been reported in animals
injected with APP RNA interference (APP-RNAi) [15] and APP ectodomain intracerebral
injections show improved cognitive function and synaptic density [16]. APP encodes type
1 transmembrane glycoprotein which is cleaved either via non-amyloidogenic pathway
(normal state) or via amyloidogenic pathway (diseased state) [17]. APP releases various
polypeptides

which

arise

possibly

due

to

alternative

splicing,

glycosylation,

phosphorylation or complex proteolysis [18, 19].

Figure 1.2 An overview of Aβ pathogenesis hypothesis
This figure demonstrates the amino acid sequence of the Aβ fragment and
the location of action of α, β and  secretases in diseased neurons during
amyloidogenic diseased pathway.
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APP comprises of 770 amino acids, out of which Aβ includes 28 residues and additional
14 residues from the transmembrane domain of APP. At cleavage site, α-secretase
cleaves and secretes large soluble ectodomain APPs-alpha (APPsα) into the medium and
C-terminal fragment (C83) is retained in the membrane, cleaved by - secretase at residue
711 releasing soluble p3 peptide. Alternatively, in diseased state abnormal cleavage is
done by β-secretase releasing truncated APPsβ and C-terminal fragment (C99) is retained
in the membrane which is further cleaved by -secretase releasing insoluble Aβ peptides.
Cleavage of both C83 and C99 by -secretase releases the APP intracellular domain
(AICD) into the cytoplasm which is soluble and translocates to nucleus for further gene
expression function [5].

1.3.2 Non-amyloidogenic pathway
APP undergoes constitutive and regulated cleavage. Enzyme α-secretase, cleaves APP
at residue16-17 of Aβ domain and yield soluble and nonpathogenic precursors. In
neurons, ADAM10 and ADAM 17 (metalloproteases) are the major α-secretases.
Processing by α-secretase and -secretase generate, a small hydrophobic fragment p3,
which is soluble and has role in normal synaptic signaling, but its exact functions are not
well elucidated. Cell-surface APP may get endocytosed resulting in endosomal production
of Aβ, which leads to extracellular release, and aggregation of Aβ. The α-secretase
processing releases large soluble ectodomain APPsα that acts a neuroprotective factor
and has a role in cell substrate adhesion. The presence of APPsα associates with normal
synaptic signaling and adequate synaptic plasticity, learning and memory, emotional
behavior and neuronal survival. Further, sequential processing releases AICD which
translocates into nucleus and facilitates nuclear signaling and gene expression and
regulation pathways [20].
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1.3.3 Amyloidogenic pathway
APP is differently cleaved in case of the diseased state. Aβ is released from APP through
sequential cleavages by β-secretase, a membrane-spanning aspartyl protease with its
active site situated in lumen and -secretase, an intramembrane aspartyl protease which
is made up for four proteins; presenilin, nicastrin, Aph-1 and Pen-2 complexed together
[21]. This complex attributes to the activity of  secretase, which produces insoluble and
neurotoxic Aβ fragments. β secretase cleavage is first and rate-limiting step, making a cut
at N terminus of Aβ. It removes the majority of the extracellular portion of the protein,
leaving the C-terminal of APP [22], which is cleaved at C- terminus of Aβ resulting in
formation of Aβ oligomers, which further polymerizes forming the aggregated plaques
(Figure 1.3).

Figure 1.3 Alternative splicing of APP and the amyloidogenic and nonamyloidogenic pathways.
Cleavage by α and  secretase in normal state and alternative cleavage by
β and  secretase in diseased state.

There are two main types of Aβ polymers, which contribute in plaque formation and induce
neurotoxicity; Aβ40 and Aβ42 isoforms. Aβ40 is abundant and neurotoxic when compared
to Aβ42, which is less abundant, insoluble and severely neurotoxic, more aggregation-
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prone and acts as toxic building fraction of Aβ assembly. Aβ40 is also neurotoxic and
easily detectable in in-vitro studies. Aβ40/42 aggregation results in blocked ion channels,
altered calcium homeostasis, increased mitochondrial oxidative stress, diminished energy
metabolism and glucose regulation, which contributes to deterioration of neuronal health
and eventually cell death.

1.4 Hyperphosphorylation of Tau and AD
In addition to Aβ, another central pathological hallmark of AD are the NFTs. These tangles
are the result of hyperphosphorylation of the microtubule-associated protein Tau and its
intracellular aggregates. NFTs are fragments of paired and helically wound protein
filaments (PHF) in the cell cytoplasm of neurons and in their processes. Tau protein is a
member of the microtubule-associated proteins (MAP) family, important for microtubular
assembly and equilibrium in neuronal cells. Tau has a microtubule-binding domain and it
co-assembles with tubulin to form mature and stable microtubule [23, 24]. It has the

Figure 1.4 Tau hyperphosphorylation
Tau phosphorylation leads to instability of the microtubule and finally
microtubule subunits fall apart leading to formation of insoluble and big
Neurofibrillary Tangles.
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capability of forming interconnecting cross bridges between contiguous microtubules to
form a proper stable network of microtubules and to hold them together. When the Tau
protein encounters the kinases released due to abundance of Aβ in the environment, it
gets hyperphosphorylated. Its hyperphosphorylation leads to its dissociation from
microtubules, the tubule gets unstable due to dissociation of tubule subunits and fall apart.
These destabilized structures then convert into big chunks of tau filaments, which further
aggregate into NFTs. These NFTs are straight, fibrillar and highly insoluble patches in the
neuronal cytoplasm and processes, leading to abnormal loss of communication between
neurons and signal processing and finally apoptosis in neurons [25] (Figure 1.4).
Extracellular Tau aggregates from neurons spread the neurodegeneration in prion-like
mechanism [26]. It has been reported that soluble Aβ controls cleavage and
phosphorylation of Tau for NFT generation [7].

Further, phosphorylation of tau is regulated by several kinases, including glycogen
synthase kinase 3 (GSK3β) and cyclin-dependent kinase 5 (CDK5), activated by
extracellular Aβ. Even though GSK-3 and CDK5 are primarily responsible kinases for Tau
hyperphosphorylation, other kinases like Protein kinase C (PKC), Protein kinase A (PKA),
Erk2 a serine/threonine kinase, caspase 3, and caspase 9 have prominent roles too, which
may be activated by Aβ [27].

1.5 GSK3Β and CDK5 in AD
GSK-3 regulates the cleavage of APP carboxy-terminal fragments. It has been showed
that lithium and kenpaullone (GSK-3 inhibitors), prevent GSK-3 expression, and contribute
to the inhibition of Aβ production [28]. Hence, GSK-3 inhibitors might indirectly interfere
with the generation of both Aβ plaques and Tau tangles in AD. GSK3β activity in the
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mitochondria has been associated with increased oxidative stress [29]. Abnormal
processing of APP leads to secretion of Aβ, which affects GSK-3 kinases leading
phosphorylation of Tau protein. This leads to aggregation of Tau filaments which are
insoluble and finally formation of huge masses of NFTs in the neurons [30].Thus, GSK3β
plays a significant role in AD pathogenesis attributing to Aβ production and Aβ-mediated
neuronal death by increasing tau hyperphosphorylation. Additionally, Aβ and CDK5
interactions affect Tau phosphorylation. This interaction leads to cleavage of adjacent
proteins releasing cleaved peptides with lower solubility and longer half-lives; they may
also phosphorylate distant proteins. Several studies focusing on identifying and classifying
kinases accountable for pathogenic Tau hyperphosphorylation point towards primary
pathogenic kinases GSK3β and CDK5, in addition to mitogen-activated protein kinase
(MAPK), Erk 1 and 2, MAP kinase (MEK), microtubule affinity-regulating kinase (MARK),
c-Jun NH(2)-terminal kinases (JNKs), p38, PKA, etc. [31, 32].

1.6 Genetic mutations: Presenelin-1 mutation and AD
APP is not the only gene associated with AD, presenilin gene (PS1 and PS2) which are
part of  secretases may also undergo mutation [33]. Moreover AD patients may be
predisposed to PS1 mutation leading to familial AD at young age [34]. The γ-secretase
complex encompasses four proteins: PS1, presenilin enhancer-2 (Pen-2), anterior
pharynx-defective (Aph-1), and nicastrin. PS, an aspartyl protease, attributes to catalytic
core of the complex. Pen-2 facilitates the maturation of PS, whereas Aph-1 stabilizes the
complex [35]. Nicastrin acts as a receptor for γ-secretase substrates. There are
179 PSEN1 and 14 PSEN2 gene mutations that participate in early-onset of autosomal
dominant AD. These mutations favor production of more toxic form of amyloid; Aβ42
compared to Aβ40 which contributes in disease progression [36].
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1.7 Epigenetics and AD
Epigenetics is the field which focuses on the interactions between genes, expression of
the genotypes and various molecular pathways which modify genotype expression into
respective phenotype [37]. Epigenetics exploring the neurological diseases, called as
neuroepigenetics has developed fairly well and has been widely studied in the CNS
associated diseases comprising of learning, motor, behavior and cognition pathologies
and disorders [38, 39]. Epigenetics is important to understand the depth of effect of
environment or paternal genes, nutritional habits, trauma, stress or learning disabilities,
exposure to chemicals or drug addiction, on the DNA and resulted structural disturbances,
mutations or changes [40, 41]. The involvement of epigenetics has recently been explored
in case of AD [42]. The onset of AD and its progress involves complex interplay of various
factors like ageing, genetic mutations, metabolic and nutritional disorders, exposure to the
environment and involvement of social factors [43]. There are fair chances that additional
factors in addition to ageing, for examples, hypertension, disorders like diabetes and
obesity, and inflammatory disorders may be inducing epigenetic changes and may induce
AD-like pathogenesis in young age. DNA methylation patterns in brain and aging is
possible [44]. From the studies involving various regions of the brain, an association
between DNA methylation and ageing was reported [45]. Since DNA epigenetic
mechanisms have a role in memory formation and its maintenance, like decrease in DNA
methylation deteriorates neuronal plasticity, leading to memory loss, it is speculated that
understanding of epigenetic mechanism is important to understand ageing and associated
complexities in AD patients [46]. In addition to DNA methylation, histone modifications
may also play an important role. Studies have explored histone acetylation in
APP/presenilin1 double mutant transgenic mice, where impairment in associative learning
was connected to H4K14 histone acetylation reduction [47]. Additionally, HDAC inhibitors
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(HDACIs) are believed to have effect on Aβ production and aggregation in AD mice.
Therefore, the studies involving their inhibitors like trichostatin A (TSA), valproic acid
(VPA), and vorinostat (SAHA) are important to target HDAC associated epigenetic
mechanism involved with ageing, to target AD [48].

1.8 Microglial infiltration during plaque formation: leading to neurodegeneration
There are extensive evidences that associate neuroinflammation with AD progression. In
addition to extracellular Aβ plaques and NFTs, microglial infiltration in response to these
aggregates exacerbates AD pathogenesis. The extracellular and intracellular Aβ and
tangles cause extreme toxicity, which results in synaptic damage, increased reactive
oxidative stress, leading to increased microglial infiltration in vicinity to the plaques.
Microglia are the resident phagocytes in the CNS, and play vital role as immune cells, in

Figure 1.5: Aβ and microglial infiltration
The extracellular and intracellular Aβ and tangles cause extreme toxicity, which
results synaptic damage, increased reactive oxidative stress that then leads to
microglial infiltration around the plaque areas.
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the maintenance of neuronal plasticity and synapse remodeling [49]. Microglia get
activated by protein accumulation which act as pathological trigger, and they migrate to
the location and initiate an innate immune response [50] (Figure 1.5).

In neurotoxic or neurodegeneration scenario, abnormal amounts of aggregated Aβ
plaques activate Toll-like receptors on microglia leading to microglial activation leading to
secretion of pro-inflammatory cytokines and chemokines [50]. In AD, microglia can bind
to Aβ via cell-surface receptors, including SCARA1 (scavenger receptor A-1), CD36,
CD14, α6β1 integrin, CD47, RAGE (receptor for advanced glycation end products) and
Toll-like receptors [51, 52]. SCARA-1 is associated with Aβ clearance of, whereas CD36
and RAGE contribute in microglial activation by Aβ [53]. Upon receptor binding of Aβ,
microglia endocytose Aβ oligomers and NFTs fibrils, which are eliminated by
endolysosomal degradation. Microglial proteases like neprilysin and insulin-degrading
enzyme (IDE) play major roles in the degradation [54]. However, in severe cases of AD,
microglial clearance of Aβ is inefficient due heavy Aβ load and increased localized
cytokine concentrations which downregulate the expression of Aβ phagocytosis receptors,
leading to minimal Aβ clearance [55]. One of the factors behind compromised AD
clearance by microglia is mutation in triggering receptor expressed on myeloid cells 2
(TREM2). TREM2 mutations are associated with increased AD severity. TREM2 is a cellsurface receptor of the Ig-superfamily highly expressed on microglia and involved in
mediating phagocytic clearance of neuronal debris. It also binds anionic carbohydrates,
bacterial products and phospholipids, and transmits intracellular signals through the
associated transmembrane adaptor DAP12 (Figure 1.6) and further phosphorylation of
downstream mediators [56].
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Figure 1.6 Aβ clearance by microglia via triggering receptor expressed on
myeloid cells 2 (TREM2)

During AD, a rare Arginine-47-Histidine (R47H) mutation of TREM2 is reported which
plays a potent role in aggravating the risk [57]. This mutation leads to inability of the
receptors to clear Aβ from the CNS contributing to Aβ accumulation and further
intensification of pathogenesis in AD patients. TREM2 mutations in microglia contribute
towards Aβ induced toxicity.
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1.8.1 Microglia and Aβ clearance
Microglia or resident macrophages of the CNS are derived from embryonic yolk sac and
later enter into CNS [58]. The role of microglia is important with respect to protection and
maintenance against the neurodegenerative disorders and their pathogenesis in the CNS
[59-62]. The primary role of microglia in a normal state is to infiltrate at the pathogenesis
site and alters its receptor expression based on the pathogenesis factors, and perform
both pro- or anti-inflammatory activity, including clearance of Aβ [63]. Due to Aβ
chemotactic effect, microglia infiltrate and gather near the dense and insoluble amyloid
plaques [64]. During excessive load of Aβ, microglia gets outnumbered and their clearance
mechanism does not work efficiently, instead this leads to more microglial infiltration which
then via pro-inflammatory cytokines (Interleukin-1 (IL-1), tumor necrosis factor (TNF-α))
and nitric oxide (NO) result in heightened levels of Aβ aggregation [65]. IL-1β is also
released due to Aβ accumulation [66]. Furthermore, the classical microglial activation is
associated with degradation and clearance of Aβ peptides through phagocytosis [67], and
clearance through G protein-coupled receptor (GPCR)-mediated signaling [68, 69].

1.9 Aβ and HIV-1 associated neurological disorders
Currently, disease associated neurological disorders are the biggest area of concern. In
this era of Anti-Retroviral Therapy (ART), with the increase in the aged Human
Immunodeficiency Virus (HIV) patients, the incidences of dementia or other neurocognitive
functions are increasing in the aged patients when compared to younger patients. HIV-1associated dementia risk in these patients is three times higher than in younger people
[70]. In AD, there are neurological dysfunctions due to abnormal accumulation of
extracellular Aβ produced by alternate cleavage of the APP. The Aβ deposition is also
reported to occur in the cortex of HIV patients when compared to age matched non-HIV
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controls [71-74]. The studies to explain the increased AD like indications, with increase in
Aβ levels, during the HIV infection are in embryonic stage. It is hypothesized that Aβ
deposition may be a common factor which aggravates in HIV-1 infection thus contributing
towards HIV associated neurocognitive disorders (HAND) and causing subtle
neurodegeneration especially in hippocampal neurons. Additionally, increased Aβ in HIV1-infected brains may affect the brain vascular functions contributing to Blood Brain Barrier
(BBB) dysfunction. If Aβ is the common factor between AD and HIV-1 disease scenarios,
it becomes imperative to address the targeting of Aβ pathway with a single and efficacious
drug molecule.

1.10 State of Art: AD Therapeutics
In AD, there are constant studies going on towards targeting various stages of
neurotoxicity by inhibiting the production and aggregation of the misfolding proteins Aβ
and Tau, their spread and induced toxicity [75]. The majority of AD therapeutic approaches
are focused on reducing levels of toxic forms of Aβ and Tau, the broad scope of
neurodegenerative processes underlying both early- and late-stage AD. Several drugs
have been analyzed and reached Phase 1, 2 and 3 of clinical trial levels. A detailed table
summarizes the drugs specific to amyloid, which are studied and target sufficiently
fundamental and proximate degenerative mechanisms [76, 77] (Table 1.1).

However, all these current therapeutics (e.g. rivastigmine, galantamine and donepezil)
target dementia associated secondary features and do not directly involve against specific
AD characteristics. Therapy failure frequently occurs due to the unfavorable
pharmacokinetics and pharmacodynamics of drugs. Pharmacotherapy failure is the result
of inadequate physical chemistry of drugs (such as hydrophobicity), unfavorable
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absorption by biological membranes, unfavorable pharmacokinetic parameters (such as
intense and plasma metabolism), instability of drugs (oxidation, hydrolysis, or photolysis),
and toxicity to tissues (hepatotoxicity, neurotoxicity, or kidney toxicity).

Table 1.1: Drugs specific to amyloid that are studied and target
sufficiently against fundamental and proximate degenerative
mechanisms

Several therapeutic strategies have been proposed and attempted for the reduction in
abnormal levels of Aβ. Further, several drugs were tested for targeting Aβ degradation,
but majority showed promising results in in-vivo studies, and unfortunately, were not able
to clear the human clinical trials. This failure creates an urgent need to develop strategies,
which are soluble, stable, target specific, to AD associated hallmarks, and potent to pass
the human clinical trials. Many of the available drugs lose their efficacy while crossing the
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BBB and are minimally bioavailable in the brain. This requires a new area of study, which
expands into efficacious neuroprotective strategies, specific to the brain. Nanoparticles
are intriguing candidates for this purpose because of their potential for multifunctionalization, mimicking the physiological mechanisms of transport across the BBB,
which is a semipermeable barrier protecting the brain from potential hazardous
substances in the blood flow; however, it also prevents the passage of vital
neurotherapeutics.

1.11 Diagnostics for AD: Labeling and imaging
The current AD diagnostics are primarily based on the neuropsychological testing. Clinical
diagnosis of AD requires neuroimaging methods and monitoring accepted biomarkers e.g.
concentrations of Aβ peptides (Aβ1-42 / Aβ1-40 ratio) as well as of total (T-Tau) and
hyperphosphorylated tau (P-tau) proteins in the cerebrospinal fluid (CSF). Amyloid
oligomers and plaque accumulation can be imaged by 1 florbetapir F-18 (or alternative C11 Pittsburgh compound B, PiB ligand) Positron Emission Tomography (PET) but
nonlinear association between Aβ content in CSF and PET scan remains of concern.
However, CSF sampling is relatively invasive and is not always well tolerated or feasible
for elderly patients. Noninvasive imaging methods such as Fluoro-2-deoxy-Dglucose
(FDG)-PET, which gives insights into the brain metabolism, are of great clinical utility.
Certainly, altered cerebral metabolism (both hyper- and hypo-metabolism) has been
associated with different stages of AD. Magnetic resonance imaging (MRI) at increased
field strength and resolution is another helpful, non-invasive approach for identification of
the functional abnormalities. MRI is utilized for detection and identification of amyloid
plaques utilizing Iron oxide nanoparticles (Fe2O3-NPs) as contrast agents or tagged with
fluorescent probes to make the detection efficient [78]. The Fe2O3-NPs are reported to
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bind to N terminal of Aβ, aiding in better imaging. Additionally, non-fluorescent or
fluorescent rhodamine tagged γFe2O3-NPs have been reported to label Aβ fibrils
selectively and remove them, by employing external magnetic field [79, 80]. In addition to
Fe2O3-NPs, there are reports of polystyrene-block-poly (n-butyl cyanoacrylate) (PS-bPnBCA) NPs encapsulating Thioflavin T, to be able to interact and target Aβ [81, 82].
Gold nanoparticles for their use in MRI as contrasting agents to study structural stages of
Aβ self-assembly [83] and Fluorescent semiconductor nanocrystals (quantum dots) for
labeling [84].

For sensing the soluble forms of Aβ in the CSF, the ultrasensitive NPs-based bio-barcode
system detecting soluble oligomers with the aid of oligonucleotide (DNA barcode)modified gold nanoparticles (AuNPs) and magnetic microparticles (MMPs), functionalized
with monoclonal/polyclonal antibodies [85] are utilized. Additionally, electrochemical
sensing utilizing click chemistry, which involves AuNPs and assembled monolayers on it,
to interact with Aβ peptide are promising [86]. Ultrasensitive electrical detection method
for Aβ42 by scanning tunneling microscopy (STM) are currently employed [87]. These
recently introduced technological and conceptual achievements considerably provide
improved AD diagnosis strategies. Upon AD diagnosis, the therapeutic and treatment
strategies can be tactfully designed. The diagnostics and imaging techniques include, for
example, nanoparticle based sensitive early phase detection of AD biomarkers in the CSF
samples from the patients. Nanomaterials can also be used as contrast agents for imaging
Aβ aggregated plaques, this highlights a very important quality of the nanmaterials which
upgrade their usage in the research experiments. It is imperative to understand the role of
nanoparticles in increasing the efficacy and bioavailability of the drug across the BBB into
the CNS.
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1.12 Need of nanotechnology as Therapeutic strategy
There are promising drugs against Aβ toxicity [88], but these drugs fail to cross and are
not available in pharmacologically significant concentrations in the CNS. Typically,
pharmaceuticals consist of small molecules, which do not cross the BBB on their own,
therefore, the nanocarriers to boost drug delivery are required. Availability of drugs in the
CNS is the major issue faced in the field of therapeutics against AD. The main reason is
the presence of a fully functional semi permeable BBB, which poses as an obstacle for
transmigration of neurotherapeutic molecules (like drugs, peptides, vectors, molecules)
across it, into the CNS.

Figure 1.7 The Semipermeable Blood Brain Barrier and transmigration
route of the Nanoparticles
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In addition, the BBB also negatively affects drug efficacy and tolerance, because large
doses of drugs are needed to reach levels above the minimum effective concentration in
the brain. Nanoparticulate systems offer an opportunity to overcome such problems and
can be used as Trojan systems for transporting active molecules across the BBB (Figure
1.7), thus reducing toxicity and improving therapeutic efficacy [89, 90].

The use of drugs in nano-platforms or nanodevices results in the enhancement of their
pharmacokinetics and pharmacodynamics, as well as reduces the toxicity. It is
advantageous in an essential aspect in nanomedicine for delivery and controlled release
of drugs onto targeted disease sites. Thus, the effectiveness of a treatment can be
increased by incorporating nanotechnology-based drug delivery systems. Some of these
new platforms, which aim to improve the bioavailability, pharmacokinetics, and
pharmacodynamics of drugs while reducing their side effects, are well studied. Recent
nanotechnology advancements propose effective diagnostic and therapeutic options.
Targeted drug delivery with the aid of nanoparticles (100nm in size) can effectively
increase the drug bioavailability cross the BBB into the CNS with minimal or no side
effects. Furthermore, these nanomaterials are designed to be biocompatible hence
reducing the toxicity, and with the modifications in their magnetic and optical properties,
they may be an efficient alternative agents for an early diagnosis [91]. For example, a
study shows the delivery of Saxagliptin (SAX); a dipeptidyl peptidase-4 enzyme inhibitor
molecule, which is explored for its activity in the therapy of AD, with the aid of the chitosanL-valine conjugate used to prepare nanoparticles encapsulating SAX. These
nanoparticles were stable and crossed the BBB efficiently [92]. In Chapter 4 of thesis, we
will have discussed about the importance of nanotechnology in effective drug delivery
across the BBB and the importance of Liposomal Nanoformulations.
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1.13 Conclusion and Future perspectives
Aβ was first sequenced from the meningeal blood vessels of AD patients and individuals
with Down’s syndrome nearly 20 years ago [93-95]. Aβ peptide was recognized as the
primary component of the senile (neuritic) plaques of AD patient brain tissue [96]. These
discoveries marked the beginning of research on AD. The cloning studies of APP gene
and its localization to chromosome 21 [97-99] in addition to the fact that trisomy 21 leads
to AD neuropathology [100] highlighted that the Aβ accumulation is the primary event in
AD pathogenesis. Additionally, mutations in the APP gene which cause hereditary
cerebral hemorrhage and amyloidosis also, may cause Aβ deposition in the AD brain [101,
102] [103-106]. AD is one of the most common neurodegenerative diseases today, but
unfortunately there is no cure available currently [107]. Several therapies are currently
employed to combat with the cognitive and behavioral deficits associated with AD.
Development of a targeted efficacious therapeutic approach against AD is still in its
developmental stage, thus the need of the hour is to look upon the cellular factors closely
associated with disease pathogenesis and target them for improvement of the quality of
life for AD patients. Cellular factors discussed in this project like Aβ, APP, and β and γsecretases, could be a key target for designing the therapeutic approach. It is utmost
important to understand the limitations of drug bioavailability in the CNS due to the tightly
controlled permeability of BBB. Nanomedicine offers an attractive approach for delivering
drugs across the BBB [108-111]. Nanotechnology pertains to nano sizes of drug and their
efficient delivery and controlled release in the brain by external magnetic field, which could
be a promising factor in therapeutics for AD. Nannotechnology is also important for
characterizing and visualization of the drug bound with nanomaterials, which makes it
easier to track and confirm their targeting efficacies. Need of the hour is to unravel the
mechanisms of the pathogenesis of AD, its early detection using state-of -the-art
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biosensing devises, specific targeting of the molecules associated with the disease
manifestation, and efficient delivery of optimum drugs to the brain using novel
nanotechnology approaches. Further, studies of comorbidities of AD with other diseases
or viral infections are important for betterment of therapeutic approaches.
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CHAPTER 2: WITHAFERIN A SUPPRESSES BETA AMYLOID IN APP EXPRESSING
CELLS: STUDIES FOR TAT AND COCAINE ASSOCIATED NEUROLOGICAL
DYSFUNCTIONS
Parts of this chapter appear in the journal Frontiers in Aging Neuroscience. Published
online 2018 Sep 27. doi: 10.3389/fnagi.2018.00291

2.1 Introduction
The overall life expectancy of people living with HIV (PLWH) has increased moderately
due to introduction of effective anti-HIV therapies [112]. As per WHO Number of AIDS
related death decreased from 1.5 million (2010) to 1.1 million (2015) globally [113]. Longer
drug (anti-retroviral) consumption and virus living cycle leads to increased prevalence of
HAND [114]. Additionally, PLWH (~2 million as per World Health Organization, 2018) are
more prone to the risk of developing neurological diseases like AD and (AD)-like
neurocognitive problems [115]. HIV-infection and associated neurological disease
synergism has become a pressing health issue to be managed, globally’ because HIV-

Figure 2.1 Disease scenario
Aβ is a common factor between HIV associated neurocognitive
dysfunctions and AD. Drug of abuse also contribute towards disease
pathogenesis.
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infection progression facilitates AD like pathology [116, 117] (Figure 2.1). However,
neurological disorders are irreversible but investigating novel therapies of better efficacy
to manage these serious disorders without side effects are urgently required.

As discussed in Chapter 1, AD is a prominent neurodegenerative disease, characterized
as a progressive impairment of memory and neurocognitive functions due to abnormal
accumulation of extracellular Aβ and intracellular neurofibrillary tangles (NFTs) [118-121].
Alternative or abnormal cleavage of integral membrane APP by β and γ secretases [122,
123] lead to abnormal Aβ processing, resulting into insoluble Aβ aggregation [124, 125]
into extracellular insoluble senile plaques [123, 126, 127]. This Aβ accumulation leads to
decreased neuronal health and stability, increased deterioration, synaptic depression
[128-130], oxidative stress [131-133], augmented neuronal dysfunctions and inflammation
[134, 135] [136].

Studies support that impairments caused by Aβ aggregation, become worst with HIV-1
infection [137, 138] and drugs of abuse. HIV patients have augmented Aβ plaques
deposition in the brain compared to HIV negative individuals [70-72]. Moreover, Aβ
aggregations are studied to be increased in cortex of HIV brains when compared to age
matched non-HIV controls [139, 140]. In other words, Aβ may be considered as a common
factor between HIV and AD associated neurological dysfunctions. HIV induced Aβ
neurotoxicity could be due to either the entire HIV, or mainly due to the presence of
neurotoxic Tat (transactivator of transcription) protein [141]. Even though ART targets all
the active HIV, Tat could still be produced by the provirus in the viral reservoirs, such as
the brain [142]. Tat protein as a neurotoxin, plays a prominent role in HIV
neuropathogenesis as it gets secreted extracellularly and has the ability to cause
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neurotoxicity in the healthy cells [143, 144]. Tat may have specific reaction with the Aβ in
the CNS and facilitate Aβ aggregation, in the CNS [145].

Neurotoxic HIV-1 Tat protein may be affecting amyloidogenesis through various indirect
mechanisms and can have direct interactions with Aβ fibers and plaques. Tat is capable
of increasing Aβ aggregation and may provide increased rigidity and mechanical
resistance to the fibrils [145]. Whereas the indirect action of Tat activity can be supported
by its interaction with human neprilysin, which is reported to function in Aβ degradation,
including both monomeric and pathological oligomeric forms of Aβ [146]. HIV-Tat inhibits
the activity of Neprilysin from degrading the amyloid oligomers into inert fragments [142].

Another factor that augments the Aβ aggregation induced pathogenesis, are the drugs of
abuse [147, 148]. These powerfully addictive stimulant drug molecules have been studied
to have an exaggerating effect during HIV infection [149]. Cocaine (coc), a very common
abused drug within PLWH, exerts malicious effects on the CNS [150-152]. Therefore, our
hypothesis is based on the concept that in the presence of coc, the additive effect of HIV-

Figure 2.2 Cocaine and Aβ40 secretion
Cocaine has a short half-life of only about an hour but its effects, predominantly
on the CNS is strong, it may contribute in Cell damage and toxicity, and also
increase the oxidative stress, therefor contributing more towards disease
pathogenesis.
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1 Tat and coc may increase Aβ aggregation, which is a common factor in aging and HIV
associated neurological disorders. Cocaine has a short half-life of only about an hour but
its effects, predominantly on the CNS, is strong and deteriorating (Figure 2.2). Therefore,
investigating therapies for targeting coc abusing aging PLWH population is one of the
main requirements to manage neurological disorders.

In this chapter, we have focused on elucidating the therapeutic properties of Withaferin A
(WA) against multiple disease-associated factors including Aβ, HIV-1 Tat and drug of
abuse, coc. WA is an active purified drug moiety extracted from ASH, isolated from the
root extract of a medicinal plant Withania Somnifera [119, 120]. WA is a steroidal lactone,
by its chemical nature, and its parent compound ASH has been traditionally used in
ayurvedic medicine from ancient times in countries like India. WA is the first member of
the withanolide class of ergostane type product to be discovered [153]. The beneficial
effects of WA has been studied in the field of tumor inhibition [154], antiangiogenic activity
[155-157], and against angioproliferative and malignant diseases like pancreatic cancer
[158], leukemia, breast cancer and colon cancer [159]. It is also studied for its antimetastasis [160] and anti-carcinogenic properties [161]. WA is also explored in the field of
apoptosis and adipogenesis inhibitor in 3T3-L1 adipocytes [162]. However, the therapeutic
ability of WA against neurological disorders, is not well studied yet. Therefore, according
to our hypothesis, we propose that WA is a neuroprotectant, which reduces Aβ40 induced
toxicity in human neuroblastoma cell lines in-vitro. Therefore, we planned a systematic
study, to explore for the first time the neuroprotective role of WA against Aβ secretion and
aggregation, and exaggerating effects of HIV-1 Tat and Coc, in-vitro.
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2.2 Methodology
2.2.1 Chemicals and Reagents
WA was commercially purchased from Sigma Aldrich (Cat# W4394 SIGMA).
Methylthiazolyldiphenyl-tetrazolium bromide (MTT; Cat# M2003) and paraformaldehyde
was purchased from Sigma Aldrich. HIV-1 clade B recombinant Tat protein (86-amino
acid) was obtained from NIH AIDS research and reference reagent program (Cat# 2222).

2.2.2 Cell Culture
The cell type used in this study are SHAPP which is a human neuroblastoma cell line
stably over-expressing human APP751 (kind gift from Dr. Jonathan Geiger, University of
North Dakota, Grand Forks, ND, USA). SH-APP cells were cultured in Dulbecco Eagle’s
minimum essential medium (DMEM; Gibco®; Life Technologies, Grand Island, NY, USA)
supplemented with 10% fetal bovine serum, 100 U/ml penicillin/streptomycin, nonessential
amino acids, and sodium pyruvate (1mM) at 37°C in 5% CO2.

2.2.3 Cell Viability Assay
SHAPP cells were plated at a density of 1×104 cells per well into 96-well plates and
maintained at 37°C for 24hrs. Cells were treated with various concentrations of WA for 48
hrs. Fresh medium containing 50μL of MTT solution (0.5 mg/mL) was added to each well.
After 3hrs of incubation, the MTT formazan crystals were dissolved in dimethyl sulfoxide
(DMSO) and viable cells were detected by measuring the absorbance at 570 nm using a
microplate reader (Molecular Devices, Sunnyvale, CA, USA).

For Tat and coc toxicity study on cell viability, we performed cell viability test using 0.4%
Trypan Blue Solution (T8154) live-dead screening. 10µl of cells were taken from the pellet
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resuspended in fresh media, after centrifugation at 1500 rpm for 5 mins, and was mixed
with 10μl of Trypan blue dye (1:1 ratio). The cells were then loaded on a cell counting slide
and counted for live count on a cell counter (BioRad TC20™ Automated cell counter).

2.2.4 Tat and Coc Treatment of SH-APP Cells
SHAPP cells (1×106 cells) were cultured overnight in T-25 flasks in complete DMEM
media. After 48 hrs, the SHAPP cells were treated with different concentrations of HIV-1
Tat (5–100 ng/ml) and coc (0.1–10 μM) and the cells and supernatant were collected after
48 hrs after the treatment. The optimized dose of Tat and coc were selected based on
their effect on increasing Aβ levels significantly compared to untreated controls. In further
experiments, 1 × 105 SH-APP cells were seeded in six wells plates and were cultured for
48 hrs. Cells were treated with optimized concentrations of HIV-1 Tat1–72 and/or coc.
2.2.5 Quantification of Aβ40 Levels
Secreted Aβ levels were measured using human Aβ40 ELISA kit as per the manufacturer’s
protocol (Thermo Fisher Scientific, Catalog# KHB3481). For secreted Aβ measurements,
SH-APP cells were cultured in six well plates and after 48 h, cells were treated with HIV1 Tat/coc in combination with WA. After 24, 48 and 72 hours the supernatant from cultured
cells were collected and protease inhibitor was added. The supernatant was analyzed by
human Aβ40 ELISA kit, as per the specific reagents and protocol provided with the kit.
Each sample was analyzed in duplicate. Cells were used for flow cytometry studies to
estimate intracellular Aβ40 level. Additionally, for studies including Tat and coc, we added
Tat and Cocaine to the SHAPP cells (80% confluent) and then after 24 hours, WA was
added to the wells (in Tat+WA and Coc+WA wells). Since WA showed best efficacy at 48
hours (established from our previous study), we collected supernatant after 48 hours to
be analyzed by Aβ40 ELISA.
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2.2.6 Flow Cytometry
Cells treated with various combinations including Tat alone, coc alone, Tat+/-WA, Coc+/WA were analyzed by flow cytometry studies to demonstrate changes in cellular Aβ40
levels, in SH-APP cells after treatment with various concentrations of WA, Tat and coc.
1×106 SH-APP cells were stained with primary anti-human Aβ40 (#PA3–16760) and
secondary anti-rabbit Fluorescein isothiocyanate (FITC)-labeled antibody (catalog
#AP187F, Millipore). Auto fluorescence of the cells was based on the unstained cells.
Cells were gated based on the secondary antibody. Accuri BD flow and Amnis® Imaging
Flow Cytometers were used for acquisition. Analysis was conducted by Flow Jo software.

2.2.7 Single-Cell Flow Cytometry
The SHAPP cells were treated with different concentrations of WA and harvested after
48hrs of treatment, washed and counted. Equal amounts of cells (1× 106) were aliquoted
in 1.5ml Eppendorf centrifuge tubes in 250μl 1X PBS. Cells were analyzed by
ImageStreamX Imaging Flow Cytometer (Amnis Corporation, Seattle, WA, USA). A
magnification of 60X was employed for all readings. Ten-thousand cells (events) were
analyzed for each sample. FITC and DAPI were excited with a 100 mW of 488 nm argon
laser. FITC and DAPI fluorescence was collected on channel two (505–560 nm) and
channel seven (560–595 nm), respectively. Intensity adjusted bright field images were
collected on channel one. Bright field area and total fluorescence intensity were calculated
using IDEAS software. Data analysis was performed using the IDEAS software (Amnis
Corporation), with proper data compensation with respect to singly stained samples. The
compensated data was then gated to eliminate cells that were out of field of focus and
doublets or debris was eliminated too.
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2.2.8 Immunofluorescence Staining and Analysis for Studying Beta Amyloid
Aggregation
To study the effect of WA on the morphology aggregation, we conducted
immunofluorescence imaging experiment. The cells were cultured to 80% confluence on
the 4-well microscopy slides and were then exposed to HIV-1 Tat+/− WA. After 48hrs, the
supernatant was discarded and the cells were fixed in 4% PFA. PFA embedded slides
were then immunostained by using Aβ40 primary antibody (1:100) and GFP secondary
antibody (1:100). Immunohistochemically stained sections were captured using the
Keyence microscope. The images were captured at a magnification of 10X.

2.2.9 Immunofluorescence Staining for Studying Effect of WA on Neuronal
Morphology
To

study

the

effect

of

WA

on

the

neuronal

morphology,

we

conducted

immunofluorescence-imaging experiment. The cells were cultured to 80% confluence on
the 4-well microscopy slides and were then treated with coc +/− WA. After 48hrs, the
supernatant was discarded and the cells were fixed in 4% PFA. PFA embedded slides
were then washed and immunostained using MAP2 primary antibody (1:100) and antiFITC secondary antibody (1:100).

2.2.10 Congo red staining for staining Aβ
SH-APP cells were grown in 2 chamber slides at a concentration of 5.0 x 103/ ml for 48
hrs. The cells were then treated with optimized concentration of WA (1µM) for further 48
hrs. Cell culture supernatant was discarded and cells were stained for Congo-red. For WA
additions, DMSO served as the vehicle to dilute the compound at a final concentration of
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1 µM. Control cultures were left untreated. After 48 hours, cells were washed with PBS,
fixed in 4% formalin for 15 min at room temperature. Again cells were washed with PBS
and then stained with a fresh alkaline solution of 0.5% filtered Congo red (Sigma-Aldrich)
at room temperature for 5 min. The cells were then washed with deionized water carefully,
and the slides were mounted in DAPI Fluoromount-G® (Southern Biotech, Catalogue No.
0100-20) and then observed through Keyence microscope. The images were captured at
a magnification of 10X.

2.2.11 Beta secretases ELISA
The effect of WA on the β secretases was studied in-vitro by measuring β secretases
levels using BACE-1 human ELISA kit as per the manufacturer’s protocol (Thermo Fisher
Scientific, Catalog# EHBACE1). For β secretases measurements, SH-APP cells were
cultured in six well plates and after 48hrs, cells were treated with WA compared to
untreated controls. The supernatant from cultured cells was collected and protease
inhibitor was added to it. The supernatant was analyzed for their β secretase levels. Each
sample was analyzed in duplicate, and was repeated three times.

2.2.12 Gamma secretases ELISA
The effect of WA on the Gamma secretases was studied by ELISA. γ secretases levels
were measured using γ secretase human ELISA kit as per the manufacturer’s protocol
(My bio Source, Catalog# MBS704513). For γ secretases measurements, SHAPP cells
were cultured in six well plates and after 48hrs, cells were treated with WA compared to
untreated controls. The supernatant from cultured cells was collected and protease
inhibitor was added to it. The supernatant was analyzed for their γ secretase levels. Each
sample was analyzed in duplicate.

31

2.2.13 Data Analysis
Results in this study are representative of three or more independent experiments.
Statistical significance was analyzed using Graph Pad Prism5 software, La Jolla, CA, USA
by performing ANOVA or the Student’s t-test for unpaired observations. The values are
presented as mean ± SEM.

2.3 Results
2.3.1 WA dose optimization and Aβ decreasing efficacy studies in SH-APP cells
To optimize the non-toxic dose of WA, different concentrations of WA (0.5–10 μM) were
treated to SH-APP cells. The dose-dependent and time-dependent (data not shown)
ELISA study demonstrated that 2μM concentration of WA at 48 hours reduces the
secreted Aβ40 in SH-APP cells significantly when compared to non-treated control,
(Figure 2.3 A) without causing cytotoxicity (Figure 2.3 B). Further, results were confirmed
with the flow cytometry and showed (Figures 2.4 A–C) dose dependent reduction in the
Aβ40 levels and the maximum reduction was reported at 2μM WA concentration without
causing cellular toxicity. Additional single cell flow cytometry and imaging also showed the
same trend highlighting the effective role of 2μM WA against Aβ40 (Figures 2.5 A,B).
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Figure 2.3 Effect of Withaferin A (WA) on amyloid beta (Aβ) secretion
(A) Cells were treated with different dose of WA and the supernatants were
collected 48 h after treatment. The supernatant collected were analyzed by
Aβ40 ELISA that demonstrated that at an optimum dose of 2μM WA, the levels
of secreted Aβ40 showed significant decrease compared to control untreated
samples. (B) The dosage of WA used for this experiment were also analyzed
for the associated cellular toxicity. The cell toxicity assay showed that the lower
doses of WA were not toxic to cells. Optimum dose of 2μM, WA did not cause
any loss in cell viability or toxicity in SHAPP cells.
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Figure 2.4 WA inhibits Aβ40 in concentration dependent manner
Panel (A) shows histograms of Aβ secretion by the SHAPP cells upon
treatment with varying dose of WA. Panel (B) shows the layover of the peaks
in one histogram, and (C) shows the quantification of the same. The cells
were treated with WA concentrations, and after 48hrs of treatment were
analyzed by Flow cytometry for determining Aβ40 levels. Flow cytometry was
used to demonstrate the expression of Aβ40 in SH-APP cells after treatment
with three different concentrations of WA. 1×106 SH-APP cells were stained
with primary anti-human Aβ40 (#PA3–16760) and secondary anti-rabbit
Fluorescein isothiocyanate (FITC)-labeled antibody (catalog #AP187F,
Millipore). Auto fluorescence of the cells was based on the unstained cells.
Cells were gated based on the secondary antibody. Accuri BD flow and
Amnis® Imaging Flow Cytometers were used for acquisition. Analysis was
conducted in Flow Jo software and Amnis® FlowSight® Imaging Flow
Cytometer and analysis by IDEAS® Image software. For each experiment,
from all events collected, FITC positive cells were gated from single cells.
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Figure 2.5 WA inhibits Aβ production
Single cell flow Cytometry was used to identify the expression of Aβ40
protein in SHAPP cells after treatment with different concentration of WA.
(A) Bar graph representing the mean ± standard error of percent of mean
fluorescence intensity. (B) Representative single cell images. We have
observed significantly reduced Aβ with WA exposure dose dependently.

2.3.2 Effect of HIV-Tat protein on Aβ production in SH-APP cells
Human Aβ40 ELISA was performed with the supernatant collected from control and WA
treated SHAPP cells to evaluate the efficacy of WA in reducing the HIV-Tat and coc
induced increase in Aβ40 levels. SHAPP cells were treated with different concentrations
of Tat (5–50 ng/ml). Figure 2.6 shows that the SHAPP cells treated with Tat exhibited upregulation of Aβ40 secretion compared to untreated control (Figures 2.6 A,B). Effective
dose of Tat (50 ng/ml) when treated with 2μM WA, showed significant decrease in Aβ40
(Figure 2.6C). Further, the results were also confirmed by the flow cytometry using Aβ40
specific primary antibody. The dose of 50 ng/ml Tat most significantly increased the Aβ
levels when compared to control (Figure 2.7 A,B).
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Figure 2.6 Tat induces increase in secreted Aβ40 levels
(A). Human Aβ ELISA analysis showing that Tat (5–50 ng/mL) increased the
secreted Aβ40 significantly in SHAPP cells. (B) Cellular toxicity assay showing
viability of the cells in the Tat treated samples. (C) 2μM WA reduced the Tat
levels significantly when compared to Tat (50 ng/mL) only treated samples. 1×
106 SHAPP cells were seeded in 6-well plates and were grown for 48hrs and
then treated with Tat protein in different doses and the cells were then incubated
for 48hrs at 37°C. The supernatant from the culture was collected and treated
with protease inhibitor (1μl/ml) and analyzed by Aβ40 ELISA (Sigma). The
results are from three independent experiments and the statistical significance
was calculated by Student’s t-test. Cell viability study was performed by Trypan
blue live dead screening, to study the toxicity levels of various Tat dose. Dose
selected for Tat treatment for further experiment was elected based on increase
in Aβ40 secretion levels and correlated with cell viability.
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Figure 2.7 Dose response
(A) Histograms showing Tat (5–100 ng/mL) increases the Aβ40 levels. SHAPP cells
were treated with different concentrations of Tat and after 48hrs of treatment were
analyzed by Flow cytometry for studying the cellular Aβ40 levels. (B) Quantification
representation of the percent positive cells.

2.3.3 Effect of HIV-Tat protein and Cocaine on Aβ production in SH-APP cells
Additionally, Human Aβ40 ELISA was performed with the supernatant collected from
control and WA treated SHAPP cells, to evaluate the efficacy of WA in reducing the coc
induced Aβ secretion. SHAPP cells were treated with different concentrations of coc (0.1–
10μM). We studied the effect of coc in the similar study pattern, and observed the increase
in Aβ40 secretion (Figures 2.8 A,B). We report that 0.1μM coc showed most significant
up-regulation in Aβ40 levels compared to untreated controls. Effective dose of coc (0.1μM)
when treated with 2μM WA, showed significant decrease in Aβ40 (Figure 2.8 C). This
result was further confirmed by the flow cytometry studies which showed a coc induced
increase in Aβ levels (Figures 2.9 A,B).
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2.3.4 Tat and coc Induced Increase in Aβ40 Levels, in combination
An optimized dose of Tat (50 ng/mL) and coc (0.1μM) alone or in combination were used
to study the decreasing efficacy of WA (2μm) in SH-APP cells. Results showed the

Figure 2.8 Coc induces increase in secreted Aβ40 levels
Similar study pattern of ELISA and flow cytometry, like in the case of HIV-1
Tat, was performed with various concentrations of coc to choose an optimized
dose of coc for further studies. (A) Coc increases Aβ40 secretion. Coc (0.1–
10μM) increased the secreted Aβ40 but the significant increase was found in
the samples treated with 0.1 μM coc. (B) Cellular toxicity assay showing
viability of the cells in the coc treated samples. (C) 2μM WA reduced the coc
(0.1μM) induced Aβ40 levels significantly when compared to coc only treated
samples.

Figure 2.9 Dose response
(A) Histograms showing coc (0.1–10μM) increases the Aβ40 levels. The cells
were treated with different concentrations of coc and after 48 h of treatment
were analyzed by flow cytometry for determining the Aβ40 levels. (B)
Quantification representation of the percent positive cells (**p ≤ 0.01; ****p ≤
0.0001; ns, not significant).
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combined effect of Tat and coc together in increasing the Aβ1–40 levels. (Figures 2.10
A,B). Individual optimized dose of Tat (50 ng/mL) and coc (0.1μM) were used for further
WA decreasing efficacy studies.

Figure 2.10 Effect of Tat and coc combination.
(A) Tat (50 ng/mL) and coc (0.1μM) individually and in combination increase
the Aβ40 levels. The cells were treated with selected Tat and coc
concentrations and combination of both, and after 48hrs of treatment were
analyzed by flow cytometry for determining the Aβ40 levels. (B) Quantification
representation of the percent positive cells.

2.3.5 WA reverses Tat and Cocaine induced Amyloid aggregates in-vitro
Immunocytochemistry studies showed that WA was able to reduce the amyloid
aggregation when compared to the untreated control SHAPP cells. The cells were grown
in the microscopic slides (eight wells) and after 24hrs of growth, the wells were treated
individually with Tat+/− WA and coc+/− WA for 48hrs and control wells were replaced with
fresh media. The cells were collected, fixed and stained with primary Aβ40 antibody
(1:100) and GFP secondary antibody (1:100). We observed that the cells exposed to Tat
and coc had strong signals for Aβ aggregation, which was mitigated by WA treatment as
observed in the Tat+WA and coc+WA, when compared to control well (Figure 2.11 A–G).

39

40

Figure 2.11 WA inhibits HIV-1 Tat induced Aβ-production, respectively
SH-APP cells were treated with HIV-1 Tat (50 ng/mL; C) coc (0.1μM; E) +/− WA
(2μM; (D,F) respectively) were compared to Control (A) and only WA treated cells
(B). After 24 h, cells were fixed and stained with Anti-Human Aβ40 overnight. Cells
were washed and stained with secondary anti-rabbit FITC-labeled antibody (catalog
#AP187F, Millipore). Images were acquired using Keyence All in one microscope
(10×). WA significantly suppressed Tat and coc induced Aβ-secretion, respectively.
Florescent intensity of these stained cells was quantified using the ImageJ software
(G) (***p ≤ 0.001; ****p ≤0.0001).

2.3.6 WA may decrease Cocaine induced neurotoxicity
To demonstrate the effects of coc and WA treatment on the SHAPP cells morphology, we
conducted immunofluorescence imaging experiment. Cultures of SHAPP cells were
grown in the chambered imaging slides for 48 hrs, and then were treated with coc+/-WA.
The cells were allowed to grow and were then washed and stained with the neuronal
marker anti-MAP2 primary antibody and then with anti-rabbit FITC-labeled antibody. We
observed that the cells exposed to coc exhibited dendritic beading (indicated by yellow
arrows) and cytoplasmic vacuoles (Figure 2.12 C) when compared to the untreated control
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(Figure 2.12 A) and WA only treated SHAPP cells (Figure 2.12 B) which showed no
abnormal beading or thickening of the dendrites. Upon treatment with WA, in coc exposed
cells (Figure 2.12 D), we observed reduced dendritic beading and more pronounced and
elongated dendrites, communicating with other neuronal cells. We quantified the numbers
of healthy dendrites (green) (excluding the distorted dendrites with dendritic beading) and
number of vacuoles like distortions in the cell cytoplasm (purple). Our quantification
demonstrated that WA treated coc exposed cells showed enhanced healthy dendrites and
less vacuoles when compared to coc treated cells only (Figure 2.13). There were no

Figure 2.12. WA reverses coc induced dendritic beading and cytoplasmic
vacuoles
SH-APP cells were treated with coc (0.1μM) +/− WA (2μM). Cells were fixed and
stained with MAP2 primary antibody overnight. Cells were washed and stained with
secondary anti-rabbit FITC-labeled antibody. (A) Control SHAPP cells and (B) WA
only treated cells showed no abnormal beading or thickening of the dendrites when
compared to (C) coc exposed SHAPP cells which exhibited heavy dendritic
beading (yellow arrows), measure of the cells being in drug-induced stress, (D) WA
treated coc exposed cells on the other hand displayed reduced dendritic beading
and elongated dendrites.
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significant changes observed in the number of cells with distorted cytoplasm between the
different treatments. This indicates that coc induces the stressed environment in the cell
culture system, which leads to neuronal damage and WA may reduce the damage caused
by coc exposure.

Fig 2.13 Quantification studies
Our quantification studies demonstrated that WA treated Coc exposed cells
A) showed enhanced healthy dendrites and B) decreased vacuoles when
compared to Coc treated cells only. There were no significant changes
observed in the number of cells with distorted cytoplasm between the
different treatments (The quantification is done from n=4 experiments).
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2.3.7 Congo red stain based quantification of Aβ in WA treated cells
We studied the effect of WA on Aβ by staining the cells with Congo red (CR) Stain. As
Figure 2.14 (20X resolution) and Figure 2.15 (10X resolution) shows, cell cultures treated
with WA alone showed reduced amyloid staining (specific to with the toxic Aβ peptide)
than in untreated SHAPP cell controls. CR also called as Amyloid stain was utilized for
histological visualization of amyloid in the cell culture, which is also termed as indicator of
amyloidosis (deposition of amyloid in tissues or cell culture). The principle behind the
staining is that CR dye forms nonpolar hydrogen bonds with the amyloid peptides and red
staining is visible when viewed by confocal microscopes due to the alignment of dye
molecules with the linearly arranged amyloid fibrils. The high pH or alkaline environment
improves the non-polar hydrogen bonding of CR with the amyloid. CR tags the Aβ peptide

Figure 2.14 Congo red staining for Amyloid shows decreased amyloid
in WA treated cells.
Control and WA treated SHAPP cells were stained by Congo red and
observed by confocal microscopy; lens 20x. We observed that Cells treated
with WA show less amyloid (red) compared to controls. Merged images show
overall visualization of cell nuclei (blue), amyloid (red), and overlap (pink).
Images are from one representative experiment of three independent
experiments.
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and stains them red when untreated SHAPP cells expressing Aβ were stained whereas
cells treated with WA had reduced levels of Aβ, therefore less staining was observed in
these control cells. We observed the cells at 10x and 20x resolutions. This study aligns
with our prior results that WA has the ability to reduce Aβ in-vitro.

Figure 2.15 Congo red staining for amyloid shows decreased amyloid
in WA treated cells.
Control and WA treated SHAPP cells were stained by Congo red and
observed by confocal microscopy; lens 20x. We observed that Cells treated
with WA show less amyloid (red) compared to controls. The mass pointed
by yellow arrows are the aggregated amyloid. Merged images show overall
visualization of cell nuclei (blue), amyloid (red), and overlap (pink). Images
are from one representative experiment of three independent experiments.

2.3.8 WA effect on Gamma secretases levels
In order to understand the mechanism, behind WA’s role against amyloid induced toxicity,
we studied the effect of WA on the γ secretases. The human γ secretases ELISA study
showed that WA did not have any effect on the level of γ secretase levels in the WA treated
SHAPP cells when compare to untreated cells, in-vitro. An optimized dose of WA (2µM)
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was used to treat the SHAPP cells for 48 hours and the cell supernatant were used for γ
secretase ELISA. We found that the level of γ secretases in treated SHAPP cells remained
same and showed no significant changes (Figure 2.16).

Figure 2.16 WA effect on the gamma secretases
No significant difference was observed in the levels of γ secretases in the
supernatant from WA treated cells when compared to non-treated control.

2.3.9 WA effect on Beta secretases levels
We studied the effect of WA on the β secretases. ELISA results demonstrated no change
in the levels of β secretases, in the WA treated cells when compared to control. An
optimized dose of WA (2µm) was used to treat the SHAPP cells for 48hrs and the
supernatant was then collected and used for the ELISA experiment. We found that WA
was not able to reduce the levels of β secretases in treated SHAPP cells, which could be
due to low detection limit of the β secretases from the supernatant samples in-vitro (Figure
2.17).
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Figure 2.17 WA effect on the Beta secretases
No significant difference was observed in the levels of β secretases in WA
treated cells when compared to untreated control.

2.4 Discussion
Neurological disorders are the biggest concern globally. Out of ~36 million HIV positive
people about 30-60% exhibit neurological disorders including dementia and AD like
pathology. In AD or AD like neurological disorders, the pathogenesis is mainly due to the
abnormal accumulation of extracellular Aβ in the CNS and is a major factor contributing
towards neurodegeneration [73]. The introduction of HAART gives a longer life span,
giving a major opportunity for developing age related disorders in these recovering
patients [163-165]. The currently available drugs against Aβ aggregation, for example,
Memantine (N-methyl-D-aspartic acid (NMDA) receptor antagonist), helps in repair of
damaged neurons [166], but does not aid in overall cure for neurological issues. Another
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drug which is very well studied for its anti-inflammatory, antioxidant and neuroprotective
properties is Cucurmin/Curcuminoid, obtained from the roots of a plant Curcuma longa
[167]. It has been reported that Curcuma may have potential role in AD treatment by
targeting Aβ aggregates and associated toxicity in the neuronal cells [168, 169].
Unfortunately, Curcuma is weakly stable and easily hydrolyzed, and gets photodegraded
and even oxidized. This makes it very challenging and leads to its minimal bioavailability
in the CNS [170].

Currently, there is no direct cure available for AD or AD-like neurodegenerative symptoms.
Since plant based products are non-toxic and easily available, we planned to study the
plant derived drug for this project. Therefore, here we have focused on a drug compound
WA, and studied its role as a neuroprotective agent against Aβ induced neuronal toxicity.
Our in-vitro studies showed for the first time that a small sized active moiety of Withania
root extract, WA decreases secreted Aβ40, in the SHAPP cells without causing
cytotoxicity. With the help of the microscopy studies, we were able to demonstrate the
protective role of WA in the SHAPP cells, which showed healthy growth in the presence
of WA. We observed that WA treatment reduced dendritic beading and cytoplasmic
vacuoles in the SH-APP cells, conferring towards protective role of WA. Our observations
on the role of WA, coincides with other studies, utilizing whole root extracts or parent
compound ASH, which show that W. somnifera whole root extract treatment promotes
neuronal health by inducing dendrite formation in-vitro [171, 172]. Moreover, our lab, in
the previous studies, has also demonstrated the role of ASH towards decreasing Aβ in the
neuronal cells in-vitro. ASH showed the reduction of Aβ in treated cells significantly when
compared to untreated controls, suggesting anti-amyloid role of ASH. Nevertheless, even
though ASH is capable of reducing the secreted Aβ, the understanding of ASH’s efficacy
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in the CNS across the BBB is minimum, as ASH molecule is big in size, and it is highly
unlikely for it to cross the BBB to reach the brain. Therefore, the systematic delivery of the
drug into the CNS and increasing bioavailability becomes a pressing issue. This urged a
need to find potent smaller molecular weight molecules with similar properties. Systematic
chromatographic studies show the various components, upon breakdown of ASH
molecule. This gave us an opportunity to study small molecule WA and assess its ability
as a neuroprotectant to target the Aβ levels.

In addition to studying the role of WA in decreasing Aβ, we wanted to target Tat protein
and drug of abuse, coc, induced increase in secreted Aβ levels. Deposition of the Aβ
plaques in the CNS is one the major phenomenon in ageing HIV patients. Neurotoxic
protein Tat is present in the brain even after ART administration and its interaction with
Aβ results in further increased levels of Aβ [173-175]. Our study demonstrates the effect
of WA on induced Aβ production upon the exposure of HIV-1 Tat. Therefore, we analyzed
the effect of HIV-1 Tat protein on the Aβ secretion in SHAPP neuronal cells and found
significantly increased Aβ production in- vitro. Our results are in agreement with other
studies, which have reported the role of Tat protein in increased neuronal Aβ secretion
[176-178]. The mechanism through which Tat increases Aβ toxicity, is still not well
understood, but some studies propose that Tat may have a direct interaction with the Aβ
fibrils, resulting in induced aggregation of monomers, towards plaques [145, 179]. This
hypothesis is supported by the Immunocytochemistry studies, which show dense
accumulation of Aβ, in the cell medium exposed to HIV-1Tat (50 ng/ml). The human Aβ40
ELISA studies, demonstrated increased concentration of Aβ40 in Tat treated samples.
This lead us to a conclusion that Tat is extremely neurotoxic with an ability to interact with
Aβ, increasing the overall toxicity, and contributing to increased aggravation of Aβ.
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Furthermore, drugs of abuse as cocaine is known to aggravate the toxic effects induced
by HIV and associated products. Amongst the most abused drugs PLWH, coc abuse has
been one of the major contributors towards the increased severity of neurocognitive
disorders in the patients [180-182]. Additionally, the percentage of drug abusers in the HIV
positive population and aging population is very high. Drug abuse/addiction and HIV/AIDS
are linked since the beginning of the HIV/AIDS epidemic. People who inject drugs
accounted for about 6% of HIV diagnoses in 2015 (CDC, 2018). Even though the
association of coc is shown with the exaggeration in HIV neuropathogenesis, the
underlying mechanisms remain unclear. We elucidate the mechanism, in this study, for
the first time, we observed the increased levels of Aβ production by coc. We observed in
the Immunocytochemistry experiments that coc affects neuronal morphology and
communications, and aggregation of Aβ in the SHAPP cells, in-vitro. This verifies the toxic
effect of coc on the neuronal cells, which contribute in the increased accumulation of the
amyloids. Coc alone and in combination with HIV-1 Tat is highly neurotoxic. These results
coincide with various in-vivo studies done by other research groups which show that the
peritoneal injection of coc in rats stimulates hyperphosphorylation of tau and neurofilament
in cortex, hippocampus and caudato-putamen regions of brain, indirectly contributing to
the Aβ toxicity [183]. These observations indicate that coc addiction may be associated
with neurofibrillary degeneration. Therefore, here we report that coc in addition to HIV-1
Tat increases Aβ secretion in vitro. To target the Tat and coc induced Aβ secretion, we
have proposed a potent bi-functional molecule WA that may act as a neuro-protectant
against Aβ neurotoxicity. Our findings suggest that HIV-1 Tat and coc introduce cellular
toxicity and cause neuronal dysfunctions by increasing amyloid secretion and modulating
neuronal morphology and communications. Moreover, accumulation and deposition of Aβ
in the brain of HIV patients (active infection or latent infection) drive the pathogenic
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cascades of neurological disorders, contributing towards aging or associated dementias
[74]. Therefore, we have proposed that Aβ deposition is induced by the presence of Tat
and Cocaine and WA is potent in reducing the secreted Aβ and induced neurotoxicity. Our
study provides new opportunities for exploring the pathophysiology and targeting the
neurological disorders. Targeting Aβ secretion will have a translational significance in the
treatment of HIV coc abusers and other neurological disorders like AD.

Further, in order to understand the mechanism of action of WA, we wanted to study the
effect of WA, if any, on the enzymes involved in the Aβ induced disease pathway. In our
in-vitro studies, upon performing the ELISA studies with the cell supernatants, we did not
observe any changes in the β and γ secretases levels. This could be due to low amounts
of these enzymes produced by the transfected SHAPP cells, which went undetected by
the ELISA, in-vitro. In order to have a better understanding, we are currently performing
in-silico studies to observe the structural interactions between β and γ secretases and WA
if any, and we plan to do in-vivo studies to understand the effect of WA on these enzymes.
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CHAPTER 3: WA AND CRID3 AGAINST Aβ INDUCED INFLAMMATION

3.1 Introduction
AD is caused by the buildup of intracellular neurofibrillary tangles made of tau protein and
extracellular amyloid-β plaques [184]. As discussed in Chapter 1, APP is cleaved by β and
𝛾 secretases and produces Aβ peptides that locate and aggregate into the extracellular
space. The formation of hydrophobic Aβ plaques cause neuronal damage by contributing
to cell death and affecting the synapses between neurons in cortical and limbic regions of
the brain. There are various aspects which add to the severity of AD pathogenesis, which
can be collected under wide constellation of medical risk factors comprising of
cardiovascular diseases, heart failure, hypertension and high cholesterol [185-190],
psychiatric risk factors like depression and anxiety [191], head injury [192, 193], stroke
[194, 195], environmental factors or lifestyle factors like smoking or alcohol consumption
[196-198] and pharmacological factors [199, 200]. Out of these contributing factors,
inflammation

is

a

potent

threat

towards

AD

pathogenesis.

AD

associated

Inflammation and alterations in inflammatory markers (interleukins, cytokines), worsen the
disease progression [201], correlating with all the associated neuropathological issues like
neuronal degeneration, neuroinflammation, microglial activation, dysfunctions in BBB
morphology and function, and finally cognitive deterioration and decline.

Therefore, it becomes important to understand the causes and the mechanism of
inflammation with respect to AD pathogenesis. Inflammation recruits more cellular
elements to deteriorate the disease progression. There have been studies focusing on the
inflammation aspects in AD, and several mechanisms have been proposed on the role of
inflammation leading towards AD [202-204].
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One of the main factors in inflammation is microglial infiltration, microglia play an important
role against pathogenic protein aggregates, because they normally engulf Aβ fibrils and
produce the pro-inflammatory cytokines and chemokines in response to a protection
mechanism. However, prominent microglial dysfunctions and associated imbalance
between cytokines production and Aβ clearance might be an additive factor towards AD
pathogenesis. The imbalance starts with the abnormal concentration of Aβ, moreover, the
neuritic plaques are extracellular residues made of highly insoluble fibrillary Aβ core
containing protein fragments of about 39-42 amino acids. The aggregation of these
plaques contribute to neurotoxicity, and boost immune response resulting in attracting
microglial cells, reactive astrocytes, and dystrophic neurites fabricated by degenerating
neuronal processes [205]. The aggregated plaques trigger series of cellular events, which
prompt host immune response. High plaque density reflects heavy Aβ accumulation, and
this accumulation in contribution with resident cells migration, stimulates acute and chronic
inflammatory responses inducing reactive oxygen species (ROS), nitric oxide (NO), and
pro-inflammatory cytokines (Tumor necrosis factor-α, Interleukin-1β and Interleukin -6),
which lead to toxicity and consequent neuronal death [206-209] and aggregation of further
more Aβ. Overall, there is a relationship between neuroinflammation caused by Aβ
plaques and neurodegeneration in the CNS.

Furthermore, the process of production of the pro inflammatory cytokine IL-1β is an
extremely controlled process and is sensitive to several contributing factors. Primarily, it
starts with the processing of Pro-IL-1β, which is a biologically inactive form, to produce
the active IL-1β. This processing of Pro-IL-1β to active IL-1β is regulated by caspase-1
enzyme. This enzyme requires processing and activation to be converted to an active
enzyme, to perform its function, and its activation is mediated by high molecular weight
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protein complexes called as inflammasomes [210]. This happens via interaction of the
Nod-like receptor protein (NLRP3) with the adapter molecule apoptosis-associated specklike protein to initiate inflammasomes production. Upon interaction, inflammasomes lead
to caspase activation [211]. The NLRP3 are able to sense a distinct range of pathogens,
insoluble factors, cellular stress and endogenous moieties like insoluble fibrils [212]. They
are not directly activated but can sense intermediate processes or intermittent species like
ROS [213]. NLRP3 protein expression levels are also a limiting step in inflammasome
activation. IL-1 increasing in AD patients could be linked to Aβ formation [214]. IL-1 is
produced by microglial cells surrounding the neuritic plaques and contribute to initiate
dystrophic neurite formation in Aβ deposits [215, 216]. Additionally, elevated IL-1
promotes an increase in P38 mitogen-activated protein (p38-MAP) kinases activity,
leading to Tau hyperphosphorylation [217, 218].

Considering the significance of inflammation as a potent factor towards disease
progression, therefore, in this project we studied the efficacy and role of WA and CRID3
(Cytokine Release Inhibitory Drug also termed as CP-424,174 and CP-412,245) against
Aβ induced inflammation. In literature, CRID3 have been studied to target ASC
oligomerization in the NLRP3 inflammasomes [219]. Therefore, one of the main
hypothesis of this chapter is that CRID3 acts as a neuroprotectant and may be able to
target IL-1β. Targeting IL-1β is extremely important, as IL-1β reduction and blockade
decreases Aβ, associated Tau phosphorylation leading to decrease in neurotoxicity, and
promote neurogenesis. We wanted to study the role of CRID3 as an anti-caspase and
anti-IL-1β drug. We demonstrated the function of CRID3 as inhibitors of IL-1β production.
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Additionally, we have discussed the role of WA in Chapter 2, for decreasing A40, but in
this chapter, we wanted to focus on the role of WA against inflammation. We wanted to
analyze the role of WA against nuclear factor kappa-light-chain-enhancer of activated B
cells (NF-κB) to understand the mechanism of WA action. NF-κB is a protein complex that
has a role in controlling DNA transcription, cytokine production and cell survival. It has
been established that the Aβ aggregates activate microglia via TLRs and RAGE receptors.
These receptors activate NF-κB, which induce the ROS production and the expression of
inflammatory cytokines (IL-1, IL-6, TNF). These inflammatory factors additionally stimulate
the astrocytes, amplifying the pro-inflammatory signals, leading to neurotoxicity [220].

In response to Aβ induced microglial infiltration, in addition to increased inflammation and
excess production of inflammatory cytokines, the NF-κB pathway is activated. The role of
NF-κB in the expression of pro-inflammatory genes including cytokines, chemokines, and
adhesion molecules has been studied [221]. Activated NF-κB is found predominantly in
neurons and glial cells surrounding Aβ plaques which induce an up-regulation of NF-κB
activity and its translocation to the nucleus. NF-κB exerts effects on almost all cell types,
playing an important function in inflammatory responses, therefore in this project, we have
analyzed the effect of WA against NF-κB mediated inflammatory response. Our
hypothesis is that WA may have a role in inhibiting the NF-κB mediated inflammatory
response by inhibiting NF-κB expression during neurological disorders (Figure 3.1).
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Figure 3.1 Hypothesis of WA and CRID3 against inflammation
The increased aggregation of Aβ leads to series of events, which contribute in
Inflammation and NF-κB plays an important role in AB associated inflammation
which can be targeted by WA. Additionally, according to our hypothesis, CRID3
may reduce Caspase -1 enzyme activity, therefore may decrease active IL-1β
levels during inflammation, therefore acting as anti-inflammatory drug

In addition to analyzing the role of WA and CRIDS individually, we have also explored the
importance of developing a combination drug cocktail with the aid of nanotechnology,
which can target inflammation caused by Aβ in the brain. Here, we have designed a
liposomal nanoformulation of CRID3 and analyzed its characteristics and efficacy to cross
the BBB. We have also combined both the drugs into one liposome, and characterized
the nanoformulation. Our future studies are designed to evaluate the functional efficacy of
these developed combination liposomes.
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3.2 Methodology
3.2.1 Cells, Chemicals and reagents
SHAPP were received as a gift from Dr. Jonathan Geiger, University of North Dakota. WA
was commercially purchased from Sigma Aldrich (Cat # W4394 SIGMA), CRID3 was
purchased commercially from Sigma Aldrich (Catalog no. PZ0280).

3.2.2 Cell culture
The cell type used in this study are SHAPP cells and were cultured in complete DMEM
(explained in Methodology section of Chapter 2). We performed mixed cultures where the
SHAPP cells were co-cultured with CHME5 microglial cell lines. CHEM5 also require
DMEM for their growth, therefore, it was easier for us to culture these cells together.

3.2.3 Cellular Toxicity assay
CHME5 and SH-APP cells were grown separately in 96 well plates (20,000 cells/well) and
incubated for 24hrs. Cells were treated with different concentrations of WA (0.5-2µM),
CRID3 (25nM-100nM) and MTM (0.1-1µM) and after 24hrs of incubation, the MTT cell
viability assay was carried out. Wells were given with the media change with one 100 µl
medium and 10 µl MTT (100 mg MTT / 20 ml PBS) was added for each well and incubated
at 37°C for 2-3 hours. After that, one volume (110µl) of stop solution was added and
incubated with mild shaking for 3 hours. The optical density of the solubilized formazan
was determined spectrophotometrically measuring the absorbance at 550 nm. The optical
density of formazan in each well is directly proportional to the cell viability and utilized for
calculations.
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3.2.4. Treatment with CRID3 and estimation of Caspase-1 and IL-1β levels
SH-APP cells and CHME5 were co-cultured (2:1 ratio) in 6 well plates for 48hrs, and
treated with optimized concentration of CRID3 and incubated for further 48hrs. Cell
supernatant was discarded and cells were trypsinized and centrifuged at 1500 rpm for 5
mins, the cell pellets were collected in 1.5ml Eppendorf. Protein and RNA was isolated
from these cells using the standard protocol from RNA and protein isolation kits. Protein
samples were used to measure Caspase-1 and IL-1β levels by the western blot assay
using anti-Caspase-1 primary antibody (Thermo Fischer, Catalogue number PA1-37232)
and anti-mature IL-1β antibody (Abcam) respectively.

3.2.5

Estimation of NF-kB mediated neuroinflammatory genes on WA treatment

SH-APP cells and CHME5 were co-cultured (2:1 ratio) in 6 well plates for 48hrs, and
treated with optimized concentration of WA and incubated for further 48hrs. Cells pellet
was collected after trypsinization and centrifugation, Cells were lysed by Lysis buffer and
RNA was isolated using the Qiagen Mini Easy RNA isolation kit using the protocol
illustrated by the kit. 1µg of RNA was used for the first strand cDNA synthesis using
SABiosciences's RT2 First Strand Kit (Cat # 330401) as per supplier's protocol. Genomic
DNA elimination step was performed before performing reverse transcription. RT²
Profiler™ PCR Array Human NF-κB Signaling Pathway kit (Qiagen Cat # PAHS-025ZA12) was used to measure 84 key genes related to NF-κB mediated signal transduction.
The array included genes that encode members of the Rel, NF-κB, and IkB families, NFκB responsive genes, extracellular ligands and receptors that activate the pathway, and
kinases and transcription factors that propagate the signal.
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3.2.6

Estimation of inflammasome mediated genes expression on CRID3

treatment
From CRID3 treated cells, RNA was collected using the standard protocol. One microgram
of RNA was used for the first strand cDNA synthesis using SABiosciences's RT2 First
Strand Kit (Cat # 330401) as per supplier's protocol. Genomic DNA elimination step was
performed before going for reverse transcription. The Human Inflammasomes RT² Profiler
PCR Array (Qiagen Cat # PAHS-097Z) was used to estimate the expression of 84 key
genes involved in the function of inflammasomes, protein complexes involved in innate
immunity, as well as general NOD-like receptor (NLR) signaling.

3.3 Results
3.3.1 CRID3 and WA do not cause cellular toxicity
Before utilizing CRID3 to test its role against inflammation, we tested the toxicity of CRID3
on the SHAPP and CHME5 cell types that we used for the experiments. We treated
CHME5 microglial cell lines and SH-APP human neuroblastoma cells for 24 hours and
observed that the range of CRID3 (5nM -2µM) was not toxic to both the cell types and did
not effect the cell viability compared to untreated controls (Figure 3.2). Based on MTT
assay, we selected the minimal concentration of CRID3 to be utilized for further
experiments.
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Figure 3.2 MTT Cell Viability Assay
SH-APP cells and microglial cells were exposed to different
concentrations of WA (50nM-1µM) and CRID3 (5 nM -2 µM). After 24
hours of incubation, cell viability was analyzed by MTT assay. We
observed no cytotoxicity with WA and CRID3 up to 2µM.

3.3.2 WA inhibits inflammatory regulated genes associated with NF-kβ pathway
To analyze the efficacy of WA on the inflammatory factors, SHAPP cells and CHME5
Microglial cell lines were co-cultured for 24hrs and incubated with WA. After 48hrs of
treatment, cells were analyzed for the expression of NF-κB mediated inflammatory
response mediators using the Human NF-κB Signaling Pathway PCR Array. We observed
that WA inhibited the expression of NF-κB (Nuclear Factor Kappa β Subunit 2) and RELA
transcription factors which plays a major role in the expression of inflammatory
chemokines and cytokines. We also observed the IKBKB and IKBKG up-regulation
(depletion of these protein activates the NF-κB) and JUN and STAT gene down-regulation.
Furthermore, we observed down-regulation of IL-1β, which plays a major role in the NFκB mediated neuroinflammation (Table 3.1).
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Table 3.1 WA inhibits NF-kβ mediated inflammatory response related genes
expression array
Human microglia and SHAPP cells were co-cultured (microglia: neuron ratio of
1:2) and exposed to WA (2μM). After 48hrs of incubation, we observed significant
down-regulation of transcription factors, pro-inflammatory cytokines and
apoptosis inducing gene expression in the culture indicate the NF-Κb mediated
anti-inflammatory activity of WA.

3.3.3 CRID3 inhibits inflammatory regulated genes associated with NLRP3 pathway
The co-culture was exposed to 100nM concentration of CRID3 (100nM concentration
chosen based on cell viability studies). After 48hrs of incubation, cells were harvested,
RNA was isolated and Human Inflammatory Cytokines & Receptors PCR Array was
performed. Results showed that CRID3 significantly down-regulated various chemokines
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and cytokines like Complement component 5 (C5), Chemokine (C-C motif) ligand 20
(CCL20), Chemokine (C-C motif) ligand 26 (CCL26), Chemokine (C-C motif) ligand 5
(CCL5) and receptors like Chemokine receptor 6 (CCR6), Interleukin 8 receptor, beta also
known as CXCR2. It also down-regulated IL-1β inflammatory cytokine gene expression
and Interleukin 33 (IL-33) pro-inflammatory cytokines Additionally, Interferon Gamma
(IFNG) gene expressing IFNγ was observed to be up-regulated (Table 3.2). This indicates
towards the anti-inflammatory property of CRID3 as it inhibits IL1- β. According to the
result from this array, we have further analyzed the effect of CRID3 on the IL1-β and its
processor Caspase-1 activities.
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Table 3.2: CRID3 inhibits inflammatory gene expression
Human microglia and SHAPP were co-cultured (microglia: neuron ratio of
1:2) and treated with 100nM CRID3. After 48hrs of incubation, we observed
significant down-regulation of chemokines and pro-inflammatory cytokines
gene expression, and cytokine receptors, in the cells, indicating towards the
anti-inflammatory activity of CRID3 and indicating towards CRID3 as
important molecule against Beta amyloid associated inflammation.

3.3.4 CRID3 inhibits Caspase-1 and IL-1β protein expression
Caspase-1 (interleukin-1 converting enzyme) and consequently released mature IL-1
production plays a major role in the neuroinflammatory response in the AD patients. In this
study, we have used various concentrations of CRID3 (25nM-100nM) to measure its
efficacy in inhibiting caspase-1 activation and IL-1 production in SHAPP cells co-cultured
with CHME5 microglia cell line (microglia: neuron ratio of 1:2). This co-culture was
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incubated for 48hrs in the presence of the CRID3 (100nM). After 48 hours, the cells were
harvested and the protein was isolated by lysing the cells in RIPA buffer. The isolated
protein was estimated for its concentration by Bradford protein estimation method. Using
western blot analysis, we analyzed the expression of both Caspase-1 and mature IL-1
protein expression. Data showed significant down-regulation of both Caspase-1 and
mature IL-1 protein levels in the samples treated by 100nM CRID3 (Figure 3.3 A, C)
compared to other concentrations of CRID3 and untreated control. The decreased levels
of Caspase-1 and mature IL-1 indicates towards potential therapeutic role of CRID3 in
the prevention of neuronal inflammation due to the accumulation of A in AD patients. We
also quantified the protein using image J software which shows significant decrease of
Caspase-1 and mature IL-1 in 100Nm CRID3 treated samples compared to untreated
controls (Figure 3.3 B, D).
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Figure 3.3 CRID3 inhibits Caspase-1 and IL-1β protein expression
SH-APP cells were co-cultured with microglia (microglia: neuron ratio of
1:2) in the presence of CRID3 (25-100nM) for 48h. Cells were harvested
and cell pellet was used in western blot for Caspase-1 (A) and IL-1β (C)
analysis. Relative protein expression was calculated using ImageJ and
observed significant inhibition of Caspase-1 (B) and IL-1β (D) protein
expression at 100nM CRID3 concentration compared to the untreated
control cells (**, p ≤ 0.01; ***, p ≤ 0.001; ****, p ≤ 0.0001).

3.3.5 Liposomal Nanoformulation of CRID3
Having studied the importance of CRID3 against IL-1β via inhibiting Caspase-1,
henceforth inhibiting amyloid associated inflammation. It became utmost important for us
to increase the bioavailability of hydrophilic CRID3 in the CNS, across the BBB. Therefore,
in this project we have attempted to design a nanoformulation for the effective
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transmigration of CRID3 across the in-vitro 3D blood brain barrier, and to analyze the drugbinding efficacy to the liposomal nanoformulation. CRID3 before being used for the
liposomal nanoformulation was studied for it toxicity on the SHAPP cells. We found that
CRID3 was not toxic to the cells. We designed the liposomes by the combination of Egg
PC, Cholesterol and Chloroform as an organic solvent. Upon utilizing the dehydration
method of liposomal preparation and loading an initial concentration of 100µg/ml CRID3
in the lipid cocktail, we were able to extrude the single bi-layered liposomes with the loaded
CRID3. According to the DLS studies, the developed CRID3 liposomes were
characterized as 480+/-30nm in size and had 78.94% drug loading efficacy (Figure 3.4).

Figure 3.4 Designed CRID3 Liposomal Nanoformulation (CRID3-LNF)
and its characterization.
The designed and produced liposome had a hydrodynamic size of 480nm and
effectively carried approximately 78.94% of hydrophilic CRID3 drug in its
hydrophilic core, and it was non-toxic to the cell culture.

66

3.3.6 Liposomal CRID3 and its transmigration across BBB
The transmigration of CRID3-LNF across the BBB caused no effect on TEER values
indicating towards no deteriorating effect on BBB resistance (Figure 3.5) and the
transmigration efficiency was approximately 50% (Figure 3.6). CRID3 being a hydrophilic
drug, is trapped in the hydrophilic core of the bi-layered liposomal nanoformulations
(Figure 3.4). The successful transmigration of CRID3-Liposomal Nanoformulation across
the BBB make it important for the drug delivery strategies. CRID3 has showed to be
decreasing IL-1β via decreasing Caspase-1 activity. In addition, aiding it transmigration
across BBB to increase its bioavailability into the CNS is a promising step towards battling
amyloid induced inflammation.

Figure 3.5 In-vitro effect of NF on the integrity of 3D BBB model
3D in-vitro BBB model was established and NFs were added on top of the BBB
and incubated for 24h at 37C to facilitate the transmigration across the BBB and
the internalization of the liposome. Integrity of BBB was determined by measuring
the Trans endothelial electrical resistance of the membrane by using TEER
measuring gauge.
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Figure 3.6 In-vitro NF transmigration across the 3D BBB model
3D in-vitro BBB model was established and NFs, free drugs, and HIV-1 Tat
were added on top of the BBB under magnetic field exposure for 24h to facilitate
the transmigration across the BBB and the internalization of the liposome. The
percentage of NF transmigration across the BBB was measured using the
FITC-labelled liposome.

Hence, the developed CRID3-LNF were stable and crossed the BBB with 50%
transmigration efficiency without causing any deteriorating effect on the resistance of the
BBB membrane. The nanoformulation has acceptable hydrodynamic size and aided
efficient transmigration of CRID3 across the BBB. Liposomes were made of egg-PC
(phosphatidylcholine) therefore, they were biocompatible and non-toxic to the barrier cells.

3.4 Discussion
Amyloid plaques, built of the Aβ protein, are the hallmark neuropathological features in
the full-blown AD brain [134, 222, 223]. Aβ in addition to causing neuronal toxicity also
plays a very crucial role in activating innate immune system and attracting microglial
infiltration leading to induction of inflammation [224, 225]. Aβ is considered as an inducer
of microglial activation and neuroinflammation, and poses as an underlying factor in the
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development of AD [204]. Microglia have dual role in AD pathogenesis, they are involved
in AD pathogenesis as when coming in contact with Aβ peptides, they release
inflammatory mediators such as inflammatory cytokines, complement components,
chemokines, and free radicals like ROS which subsidize further Aβ production and its
aggregation into big and insoluble plaques [226]. There is continuous dependent
relationship between Aβ, microglial infiltration, production of inflammatory mediators and
induction of inflammation (Figure 3.7).

Figure 3.7 The interdependent relationship between between Aβ,
Microglial infiltration, production of inflammatory mediators and finally
inflammation.
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This interdependent pathogenesis pathway requires combination drugs cocktail to target
inflammation and Aβ induced toxicity. Aβ aggregation activates microglia via TLRs and
RAGE receptors and in turn these receptors activate NF-κ B. Increased activity of NF-κ B
induce ROS production and the expression of inflammatory cytokines [227]. Therefore, in
this chapter, we have studied the drugs WA and CRID3 for their roles against Aβ and Aβ
induced inflammation.

The nuclear factor NF-κB pathway is a pro-inflammatory signaling pathway, inducing
expression of pro-inflammatory genes including cytokines, chemokines, and adhesion
molecules [221]. The NF-kB pathway includes Nuclear factor-κB (NF-κB)/Rel proteins
include NF-κB2 (p52/p100), NF-κB1 (p50/p105), c-Rel, RelA/p65, and RelB proteins.
These proteins together play role as dimeric transcription factors regulating innate and
adaptive immunity, inflammation and stress response associated gene expressions. NFκB/Rel proteins are bound and inhibited by nuclear factor of kappa light polypeptide gene
enhancer in B-cells inhibitor (IκB) proteins. But with the introduction of pro-inflammatory
cytokines, Lipopolysaccharides, fibrillar antigens etc. there is an activation of an I kappa
B kinase (IKK) complex (IKKβ/IKKα), which then phosphorylates IκB proteins leading to
IκB ubiquitination and proteasomal degradation, and releasing the NF-κB/Rel complexes.
Active NF-κB/Rel complexes undergo post-translational modifications and translocate to
the nucleus where, with the help of other factors like Stat, induce target gene expression.
In the alternative (or non-canonical) NF-κB pathway, NF-κB2(p100)/RelB complexes are
inactive in the cytoplasm and activate IKKα that phosphorylate NF-κB2 p100 leading to its
ubiquitination and proteasomal processing to NF-κB2 p52 which then translocates to the
nucleus and induces target gene expression [228-230].
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Since a wide array of diseases, including cancer, are rooted in inflammation, there is a
surge in interest in understanding the mechanistic regulation of inflammatory responses.
NF-κB activation is widely implicated in inflammatory diseases like rheumatoid arthritis,
Atherosclerosis, Asthma, Multiple sclerosis, chronic obstructive pulmonary disease etc.
[231] and therefore development of anti-inflammatory drugs targeting NF-κB are currently
in focus [232]. Aβ aggregation may indirectly result in elevated NF-κB. We here
hypothesized that WA may be able to inhibit NF-Kb associated inflammation. With the NFkB signaling array studies, we observed that WA inhibits inflammatory regulated genes
associated with NF-kB pathway. The NF-κB assay experiment demonstrated that WA was
able to inhibit the expression of NF-κB2 (Nuclear Factor Kappa B Subunit 2). NF-kB2
encodes a subunit of the transcription factor complex NF-kB. The NF-kB complex is
expressed in numerous cell types and functions as a central activator of genes involved
in inflammation and immune function [233]. Several studies have shown the regulation of
the NF-ΚB2 (p100) in response to the inflammatory cytokines and have shown that IL-1,
induces p100 expression at mRNA and protein level [234]. Therefore, if WA is downregulating NF-ΚB2 that means it may be equally capable of indirectly down-regulating IL1. NF-kB is composed of NF-ΚB1 or NF-ΚB2 bound to either REL, RELA, or RELB. The
amplest form of NF-kB is NF-ΚB1 complexed with the product of this gene, RELA (also
known as p65), which is a REL-associated protein participating in NF-κB heterodimer
formation, aiding nuclear translocation and its activation [235]. We also observed the
down-regulation of RELA transcription factor which plays a major role in the expression of
inflammatory chemokines and cytokines. NF-κB activity at inflammation sites activates the
canonical pathway and RelA containing complexes. Therefore, down-regulation of RelA
indirectly down-regulates NF-kB. In addition to these, we have also observed the IKBKB
(Inhibitor of nuclear factor kappa-B kinase subunit beta) and IKBKG (NF-kappa-B
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essential modulator) up-regulation. IKBKB phosphorylates components of the NF-kB
signaling pathway including IKBKG, NF-kB subunits RELA and NF-ΚB1, as well as IKKrelated kinases TBK1 and IKBKE. This phosphorylation may help in preventing the
overproduction of inflammatory mediators, highlighting the role of WA against NF-κB
regulation, proving its anti-NF-κB potency. Furthermore, we have observed up-regulation
of NF-ΚBIA (NF-kappa-B inhibitor alpha) which inhibits the activity of dimeric NF-κB /REL
complexes by trapping REL dimers in the cytoplasm [236] and NF-ΚBIE or IKBE (NFkappa-B inhibitor epsilon) which Inhibits NF-κB by complexing with and containing it in the
cytoplasm [237]. Additionally, most importantly we observed that WA was able to
downregulate IL-1β significantly compared to untreated controls. IL-1β is a potent proinflammatory cytokine and its production includes CASP1 activation, pro-IL-1β processing
and secretion of the active IL-1β leading to inflammasome assembly [238]. We showed
that WA treatment modulates the level of multiple factors in co-cultured cells, associated
with NF-κB down-regulation. Therefore, a reduction in IL1-β may be associated with the
inhibition of NF-κB by WA treatment. Studying NF-κB is important, as some Insilico studies have showed the promoter regions of IL-1β to be possessing NF-κB
transcription factor sites. Therefore NF-κB down-regulation may be connected to IL-1β
down-regulation [239] All these factors assert the important role of WA against
inflammation and WA inhibits NF-kB mediated neuro-inflammation.

In addition to WA, we have also deciphered the role of CRID3. Microglial cells produce
inflammatory cytokines in response to various stimuli like insoluble toxic protein Aβ [240].
The inflammation array studies demonstrate that increased inflammation increases the
inflammatory

cytokines/chemokines

levels,

but

CRID3

reduced

Aβ

induced inflammatory mediators and cytokine production, including IL-1β and Caspase-1.
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However, we could not observe its effect on intracellular ROS in SHAPPs, but it could be
a restriction of in-vitro experiments. We will try to look at ROS production in our ongoing
in-vivo studies. Upon analyzing the array data, we found that CRID3 down-regulated IL1β significantly compared to untreated controls. To assess the potency of CRID3 against
IL-1β, we performed protein quantification by utilizing western blot technique and
observed the down-regulation of IL1-β and Caspase-1 protein expression upon treatment
with CRID3. The cytokine cascade in inflammatory processes is complex that involves
stimulants, glial cells, neuronal cells and immune system. IL-1β is one of the important
factors, it is a pro-inflammatory cytokine that has been associated in inflammation and
pain [241]. The IL-1 cytokine family is primarily associated with acute and chronic
inflammation [242]. To better understand the inflammatory responses it is important to
understand the role of inflammasome complex proteins like IL-1β which has main role in
inflammasome activation [243, 244]. We saw the reduction in IL-1β, in WA and CRID3
treated samples that could be due to reduced pro IL-1β and reduced active caspase-1.
Although IL-1β secretion and reduction might depend on various factors [245], but
according to our study it may be due to NF-κB reduction and anti-inflammasome role of
WA and CRID3.

The cytosolic segment of IL-1 receptor contains the Toll-IL-1-receptor domain that is
common in Toll-like receptors, which respond to external factors like viruses or microbial
factors. IL-1β is studied to be a therapeutic target against inflammatory diseases and its
decrease is important for disease reduction [246]. Further, the assay demonstrated that
CRID3 down-regulates various chemokines and cytokines like Complement component 5
(C5), Chemokine (C-C motif) ligand 20 (CCL20) also called as Macrophage Inflammatory
Protein-3 (MIP3A), Chemokine (C-C motif) ligand 26 (CCL26) also called as Eotaxin-3 or
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Macrophage inflammatory protein 4-alpha (MIP-4), Chemokine (C-C motif) ligand 5
(CCL5) also known as RANTES (regulated on activation, normal T cell expressed and
secreted) which have been studied for their chemotactic properties. It also down-regulated
the receptors like CCR6 and CXCR2. Our studies highlight that CRID3 has role against
IL-1β in lower concentrations and causes no cytotoxicity.

Therefore, in conclusion it is important to say that the chronic deposition of Aβ stimulates
the persistent activation of microglia and results in increased IL-1β levels (IL-1β requires
caspase-1 for activation). Caspase-1 activity is controlled by inflammasomes. The NLRP3
inflammasome can sense inflammatory crystals and aggregated proteins, including Aβ.
Therefore, inhibition of NF-kB mediated inflammatory response and inhibition of NLRP3
mediated inflammatory response is important. We introduce cytokine release inhibitory
drugs or CRIDs as inhibitors of secretion of IL-1β. Therefore, in this study, use of CRID3
will be useful for the prevention of NLRP3 mediated inflammatory response induced by
Aβ. These amyloid peptides in turn lead to increased oxidative stress and increased
inflammation [247]. Microglia release pro-inflammatory cytokines and (TNFα) that upregulate β and γ secretases and lead to increases in Aβ42, therefore a cocktail of antiamyloid and anti-inflammatory drug and its delivery to the CNS was the most important
aim of this project.

Having studied the importance of CRID3 against Aβ associated inflammation, the next
important and pressing issue is the bioavailability of the drug CRID3 across the BBB into
the CNS. For this, we devised the strategy of the development of liposomal
nanoformulation of CRID3 separately and as a combined cocktail formulation with WA.
Liposomes are one amongst the common, efficient, biocompatible and well-studied
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nanocarriers for the drug delivery with increased efficacy and improved targeted delivery.
Liposomes are exploited for their ability to stabilize drugs, increase cellular and tissue
uptake, and refining and increasing the bioavailability and bio distribution of therapeutic
drugs [248-251]. Based on these benefits of liposomes, we decided to design liposomes
as a carrier for CRID3. The developed liposomes were loaded with CRID3, which being
hydrophilic was packed in the hydrophilic core of the liposome. The drug was loaded in
the liposome with great efficacy and did not contribute in increasing the hydrodynamic size
of the liposomal complex. CRID3 loaded liposomal nanoformulation transmigrated across
the cellular layer of the in-vitro BBB model which was measured by the transendothelial
electrical resistance (TEER) measurement method [252]. Measuring TEER ensures that
the developed nanoformulation is not toxic to the BBB and passes through the without
effecting the permeability or the stability of the membrane. The designed liposome based
on its efficacy can be of immense therapeutic importance against inflammation and toxicity
caused by Aβ. Moreover, we have developed a nanoformulation with both WA and CRID3
to act as one formulation, multiple effects strategy. Incorporation of WA in the hydrophobic
and CRID3 in the hydrophilic part of liposomes, will help us target Aβ and inflammation
associated with Aβ with just one nanoformulation. This study is ongoing and is part of our
future perspectives to evaluate its efficacy in-vivo. This strategy could be of immense
therapeutic potential against Aβ induced inflammation in AD or AD- like diseases.
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CHAPTER 4: LIPOSOMAL NANOFORMULATION OF WITHAFERIN A AS A
PROMISING NANOCARRIER AGAINST AMYLOID BETA

4.1 Introduction
The ageing population is prone to age-related neurological disorders, including motor
disorders, memory deficit, dementia and various other neurological issues [253, 254].
[255].The most fatal and complex of neurological diseases is AD or AD like pathology
[256] characterized by progressive loss of synapses and neurons, due to buildup of
amyloid plaques, and neurofibrillary tangles, and associated inflammatory factors leading
to excessive toxicity in the CNS [257]. The presence of cerebral amyloid deposition are
confirmed by studies using positron emission tomographic (PET) brain scans with the aid
of amyloid tracers, which also suggest that Aβ may pose as one of the important target for
AD detection and therapeutics [258]. This hypothesis has currently lead to a current
surplus of drugs being investigated and developed against AD or AD-like diseases
targeting Aβ as one of the potential biomarkers. The researchers are continuously looking
for new options to treat AD and associated dementia.

Drug developing field faces a major challenge, in the areas of methods development for
increasing the bioavailability of the drugs in the CNS to the physiologically relevant levels.
The shortcoming of the current drug strategies are the minimalistic availability of the drugs
in the patient brain. The presence of semi-permeable BBB at the brain-blood junction
makes it nearly impossible for the drug molecules to penetrate through and reach the brain
[259-262]. Preliminary strategies to overcome the transportation issues involved passive
diffusion of small lipophilic molecules but it was not acceptable, as this strategy could not
include the vast majority of potential therapeutic molecules. Nevertheless, next approach
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was to develop water soluble small molecular size drugs, to facilitate their transport across
BBB via paracellular diffusion pathway, but these molecules failed to penetrate past the
tight junctions of endothelial cell layers [263]. Therefore, since the drugs do not reach the
brain in the efficacious concentration, it has become urgent for the employment of the
emerging technologies to aid in effective delivery of anti-amyloid drugs across the BBB
effectively into the CNS.

Currently, nanotechnology has gained tremendous interest over the past several decades
in the field of drug delivery. Nanotechnology employs various targeted nanosystems as
drug carriers, which are highly capable in increasing therapeutic efficacies as they have
effective role in regulating the bio distribution, circulation time, stability and solubility of the
drugs. All these factors are immensely important for a successful therapeutic
advancement [264-266]. Smart nano-systems are being currently designed for effective
delivery of the drugs to the unapproachable body parts like brain and spleen. These
nanoparticles are in range from 50-500 nano-meter and can be tagged by fluorescent
factors to help with the visualization purposes upon the administration of the Nanoparticles
in the targeted areas. They can be targeted to the respective areas where it is required
the most and the drug binding stability and on-demand release of the drugs contribute as
positive add-ons to the emerging nanotechnological advances.

There are various nanoformulations, which are being developed and tested for their
efficacy in drug delivery. Out of them, liposomal nanoformulations have been investigated
as effective drug delivery agents. Liposomes have the ability to co-encapsulate the drug
of interest (hydrophobic or hydrophilic) in addition to the contrast agents. These contrast
agents can help in tracking the drug and its distribution towards the target area [267-269].
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The BBB is a sensitive biological dynamic barrier made up of tight junctions (TJs) between
endothelial cells lining the blood vessels, end-feet of astrocytes, and a basement
membrane. Role of pericytes is also important in increasing the stability of the membrane
and the tight junctions. Together these cells regulate the CNS milieu and are essential to
maintain the uncontaminated microenvironment of the brain [269-271]. The barrier is so
tightly packed that it leaves immensely little chance for an alien molecule to pass through.
The transport properties of the semi permeable BBB is limited to cells, water and ions,
and is extremely selective to solutes, nutrients, therapeutic agents and drug carriers. TJs
have a regulating effect, and reduce the ion and other hydrophilic solutes permeation by
paracellular pathway, therefore contributing as the physical barrier [272]. Nonetheless,
BBB also poses as a barrier against the delivery of the vital drugs, which are of immense
importance to treat CNS associated diseases. Therefore, it requires serious efforts to
devise nano-carriers for the improvement of drug delivery across the BBB to target and
treat neuropathological conditions like dementia, AD, Parkinson’s, and HIV associated
dementia.

Amongst various strategies for increasing drug delivery including physical methods like
focused ultrasound [273], chemical modifications like modifying a drug into a prodrug to
enhance

lipophilicity

[274]

and

biological

modifications

like

tagging

drugs

with macromolecules (proteins and peptides to aid BBB transmigration by endocytosis)
[275], the strategy of nanoparticles based drug-delivery system is competent and more
efficacious and promising [276].

With concern to efficacious hydrophobic drug delivery across the BBB, the most feasible,
promising and targeted drug delivery system against AD are Liposomes. Liposomes are
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biocompatible and flexible in nature, and have the potential to carry multiple therapeutic
molecules across the BBB. In the early 1960s the development and therapeutic
prospective of liposomes was studied 1961, but their importance as effective nanocarriers
has been understood very recently in the field of neuroscience [277, 278]. Liposomes are
bi-layered lipid entities which incorporate hydrophilic or lipophilic therapeutic agents,
where hydrophilic drugs are entrapped in the aqueous core, and lipophilic compounds are
contained in the hydrophobic region of the lipid bilayer [279, 280].

There are various studies where liposomes are employed as the career for the drug
delivery [281]. Liposomes demonstrate high efficiency for nose-to-brain transport, for a
promising strategy for drug delivery in the brain [282, 283]. The current study incorporates
the design of modified targeted liposomes, which are efficient across BBB and can focus
on the specific molecular targets in the CNS concerning AD (Figure 4.1).

Studies suggest that liposomes are able to penetrate in the cells [284] through, either with
the aid of phospholipid bilayer of the liposomes on its own which might enable
transportation or by taking benefit of the negative charge of the BBB. The lipids 1,2dipalmitoyl-sn-glycero-3-phosphocholine

(DPPC),

Phosphatidylcholines

(PC)

and

cholesterol component of liposomes help enhance the cellular uptake [285]. Therefore,
they serve as great research alternative approaches for drug delivery in case of CNS
diseases. The approach in this chapter is based on liposomal delivery of the
neuroprotectant WA, which is discussed in previous chapters, decreases Aβ induced
toxicity and inflammation. Our laboratory has previously studied the importance and
mechanisms of nanoparticles and theranaustics in the field of drug delivery [264]. Here
we have focused on liposomes, which have been widely researched for diverse medical
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applications including hydrophobic or hydrophilic drugs delivery, non- toxicity and easy
release of the drugs at the target, allowing for immense potential in various biomedical
applications.

In the present in-vitro study, we have focused on the drug binding properties of liposomal
nanoformulation with WA, to aid its transmigration across the BBB and increase WA’s
bioavailability. This may be a promising strategy for AD, AD-like pathology and HIV
associated dementia patients. Our approach started with the liposomal synthesis process
employing multiple combinations of lipids versus cholesterol ratios and then the final
developed drug loaded liposomal products were characterized for their properties. Special
care was taken to investigate the subsequent effect of each condition on the morphology
of the liposomes, and the best-suited dehydration time, hydration temperature and lipid
ratios were confirmed. Developed liposomes were characterized and studied for their
transmigration and efficacy across BBB.
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Figure 4.1 The flow-plan of the strategy to increase the bioavailability
of the drugs in to the CNS across the BBB

4.2 Materials and methods
4.2.1 The 3D in-vitro BBB model
Primary human brain microvascular endothelial cells (HBMESs), human astrocytes (HAs)
and human pericytes (HPs) cells were cultivated as per the provider’s recommendations
(ScienCell Research Laboratories, CA, USA). The BBB model was established as
described by Persidsky et al. [286]. In brief, the in-vitro BBB model was developed in a bicompartmental trans-well culture plate (product 3415; Corning Life Sciences, Mexico). The
upper chamber of this plate is separated from the lower chamber by a 10μm thick
polycarbonate membrane possessing 3.0μm pores. In a sterile, 24-well cell culture plate
with a pore density of 2×106 pores/cm2 and a cell growth area of 0.33 cm2. 2×105 HBMEC
were grown and 1×105 each of HA and HP were grown to confluence on the upper
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chamber and underside of the lower chamber, respectively. The trans-wells were flooded
with the combination media (ECM: AM: PM=2:1:1), the upper chamber can hold up to
600μl media, and lower chamber can hold 500μl of media. After the cells were adhered to
the transwell inserts, these inserts were transferred to 24 wells plate. This setup was
cultured at 37°C and the media was changed every 48 hours. The 3D in-vitro BBB was
used for further experiments after 5 days. Intactness of the in-vitro 3D BBB model was
determined by measuring the TEER, using Millicell ERS microelectrodes (Millipore) on the
5th day after the initial seeding.

4.2.2 BBB transmigration assay
Transmigration study of drug-loaded WA liposomes was conducted on the 5th day of the
BBB culture, when ideal integrity of the membrane was achieved, as established by TEER
measurement experiment. To assess the effect of liposomal nanoformulation on the
integrity of the in-vitro BBB model, transmigration assay was performed to measure
paracellular transport of FITC-dextran [287]. 100 mg/mL FITC-dextran (Sigma-Aldrich, St
Louis, MO, USA) was added to the upper chamber of the inserts and further incubated for
6 hours. Samples were collected from the bottom chamber after 6 hours, and relative
fluorescence was measured at excitation wavelength 485 nm and emission wavelength
520 nm, using a Synergy HT multimode microplate reader (BioTek Instruments, Inc.,
Winooski, VT, USA) multimode microplate reader instrument. FITC-dextran transport was
expressed as percentage FITC-dextran transported across the BBB into the lower
compartment compared with negative (untreated) control. WA liposomal nanoformulation
was added to the apical chamber and incubated at 37°C for 48 hours. Supernatant were
collected from the lower chambers and percentage of transmigration was analyzed at
different points, using an ammonium thiocyanate-based photometric assay [288].
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4.2.3 Synthesis of WA Liposomal Nanoformulation
For the experiments, we used fluorescent and non-fluorescent liposomes. The liposomes
were synthesized using the dehydration method. For the preparation of Multilamellar
Liposomes (LMV), the seed solution was prepared by adding 80µL of egg-PC lipid, 20µL
of Fluorescent egg-PC (100µL of egg-PC in case of non-fluorescent liposomes), 0.5mg/ml
of Cholesterol, and was made up to total volume of 200µL by dissolving the lipids in
Chloroform, in a clean and dry glass tube. The solution was then mixed well for 1 minute
and loaded in the vacuum Rotary evaporator system (Yamato RE-201 Rotary Evaporator,
BM-200) for the evaporation of the organic solvent chloroform. The tube was dipped in the
hot water bath, and water temperature was maintained at 40°C. The setup was set at mild
rotations, for facilitating proper mixing and dehydration of the chloroform. After 30 minutes
of dehydration, the tube was checked for the dried up thin and translucent film at the base
of the glass tube. 1ml of fresh PBS (1ml) was added to the glass tube. The solution was
carefully vortexed for a couple of minutes until the film dissolved completely in the PBS
and the mouth of the tube was sealed with parafilm to avoid contamination. The tube was
kept in water bath for 1 hour with regular vortexing intervals at every 20 minutes. The
temperature of the water bath was maintained at 40°C. These LMVs were extruded into
large unilamellar Vesicles (LUVs). Meanwhile the mini- extruder setup was placed on a
hot plate (502-P, PMC Industries, Inc., San Diego, CA, USA) for approximately 30 mins.
A thermometer was inserted into the well provided in the heating block, and was allowed
to reach the temperature of 50°C. After rehydrating the LMVs for 1 hour, and once the
sample was fully hydrated, we loaded the sample into one of the gas-tight syringes and
carefully place into one end of the Mini-Extruder. Second empty gas-tight syringe was
placed into the other end of the Mini-Extruder set-up. The fully assembled extruder
apparatus was inserted into preheated extruder stand. The LMV sample was pushed
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across the 0.2µm membrane by gently pushing the plunger of the filled syringe until the
lipid solution is completely transferred to the alternate syringe via porous membrane and
the membrane filter. The step was repeated 5 times making 10 passes through membrane
as more the passes though the membrane, the more homogenous the lipid solution
becomes. The final extrusion filled up the alternate syringe, and the solution was collected
from there into the Eppendorf 1.5 ml tubes (Figure 4.2) [289-291]. The filtered solution
was then ultra- centrifuged at 100,000 g for 1 hour at 4°C. The supernatant was collected
(unbound drug) and the pellet (Drug bound LUVs) was re-suspended in 1 mL of PBS. The
drug binding was calculated indirectly by subtracting total drug from the unbound drug,
measure by spectrometer.

Figure 4.2 Preparation of Liposome Nano formulation
Liposome was prepared by hydration method using variant ratios of lipids
dispersed in organic solvent Chloroform
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4.2.4 Characterization of liposomes size and bound drug calculation
A zetasizer was used to calculate the average size of the developed liposomes. The drug
bound liposomes from the pellet of the centrifuged liposomal samples were redispursed
in PBS and measured for their size. The amount of unbound drug was predicted by
analyzing the concentration of unbound drug in the supernatant at 230nm and hence
indirectly the amount of bound drug was calculated by subtracting unbound drug from the
initial drug concentration. The drug binding was calculated in percentage by keeping initial
concentration of the drug as 100%. All these concentrations were calculated based on the
standard curve, which was prepared using different concentration of WA read at 230nm
wavelength.

4.2.5 Toxicity studies: Trypan Blue Cell viability test
The cells were grown at the concentration of 0.1x106/2 ml and were incubated for 48 hours
at 37°C. After 48 hours, the cells were trypsinized and collected. The cells were
centrifuged and the pellet was re-suspended in 1ml of fresh media. 10µl of cells
suspension was mixed with 1X Trypan blue dye in the ratio of 1:1 and was loaded onto
the slides and read by viable cell counter. The control was considered as 100% and the
viability of other samples were calculated with respect to control.

4.2.6 AB40 ELISA with Liposomal NF
Secreted Aβ levels were measured using human Aβ40 ELISA kit as per the manufacturer’s
protocol (Thermo Fisher Scientific, Catalog# KHB3481). For secreted Aβ measurements,
the SH-APP cell supernatant were collected from the basal side of the BBB. Protease
inhibitor was added to the supernatant to avoid protein degradation. The supernatant was
utilized as samples for the AB40 ELISA as per the specific protocol provided with the kit.
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4.2.7 WA Drug release kinetics from the Liposome by Dialysis membrane method
WA Liposomes were prepared and were re-dispersed in final volume of 1ml PBS. 500μl
of WA Liposomal solution was then loaded to the micro Float-A-Lyzer with the help of 1ml
syringe. The micro Float-a-Lyzer (The Spectra/Por Micro Float-A-Lyzer) has an ultrapure
Biotech Grade Cellulose Ester (CE) tubular membrane with a volume size of 400 - 500 µl
with the Molecular weight cut off range of 3.5-5kD. The set up was placed in a glass flask
of 200ml volume filled with 60ml of dissolution medium Phosphate buffer (pH 7.4). The
speed of rotation for this setup was 2000rpm and the temperature was maintained at 25
± 0.5⁰C. Aliquot of 1 mL at each time points were withdrawn and replaced with 1mL of
phosphate buffer pH 7.4 (Time Points:0, 0.5,1,1.5,2,4,8,10,17, 18, 19, 23and 48 hours).
The samples were analyzed by UV spectrophotometry analytical method at 230nm, and
the drug released was calculated based on WA standard curve. The percent release was
calculated accordingly.

4.2.8 Data Analysis
The experiments were repeated at least three times and the values obtained were
averaged. All the results were expressed as mean ± standard error of the mean. Statistical
analysis of two groups was performed by Student’s t-test, while more than two groups
were analyzed using one-way ANOVA. Data analysis was performed with the Statistical
Program, Graph Pad Prism software (La Jolla, CA, USA).

4.3 Results
4.3.1 In-vitro 3D Blood Brain Barrier model
The in-vitro 3-D Blood brain barrier was made with the primary human CNS cells; HBMEC,
HA and PA. The intactness of the blood brain barrier was measured by measuring TEER
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values which were +/- 230 indicating towards, intactness of the BBB membrane. This intact
BBB was used further for the treatment with the nanoformulations and for the
transmigration experiments. Figure 4.3 is the representative diagram of the developed invitro 3D model of the BBB.

4.3.2 Development and characterization of NF
Schematic representation of the developed liposomes loaded with neuroprotectant drug
WA is shown in Figure 4.4. The bi-layered liposomes were prepared and characterized
for their size, toxicity and drug binding efficiency.

Figure 4.3 Developed in-vitro 3D BBB model demonstration
This figure demonstrates the strategy of designing the in-vitro 3D BBB model. The
Endothelial cells are grown at the apical side and Astrocytes and Pericytes were grown
at the basolateral side. The cells were allowed to grow and firmly attach to the
membrane in the trans-well insert. The media used was a combination media of AM:
PM: ECM in a ratio of 1:1:1. The BBB was allowed to grow at 37°C and 5%CO 2 and
then the inserts with attached cells were transferred in the new wells with SH-APP
growing at the base of these wells. The TEER was measured after 5 days, to assess
the intactness of the BBB.
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Figure 4.4 Schematic liposome structure
The figure demonstrating the phospholipid bilayer, consisting of hydrophilic
head and hydrophobic tail. The entrapment of hydrophobic drug WA by the
lipid bilayer is also demonstrated.

The developed WA-liposomal nanoformulation (WA-LNF) demonstrated the average
size of approximately 400 ± 50nm diameter (as they were only bath sonicated and not
probe sonicated), and they were uniform in size and shape as studied by Dynamic light
scattering (DLS) analysis used for hydrodynamic size analysis, as shown in Table 4.1.
The loading efficiency of liposomes were calculated indirectly by estimating unbound
drug in the supernatant after ultracentrifugation of the prepared liposomal solution. We
found that the developed liposomes had a bound drug concentration of 14.14 µg/ml,
which was approximately 28% drug binding efficacy when compared to the initial 50
µg/ml loaded drug concentration while preparing the liposomes. To encapsulate the
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hydrophobic WA in the liposome, different solvent combinations (Chloroform or
Chloroform to Ethanol in 90:10 or 50:50 ratios) were used for the synthesis of
liposomes. Table 4.1 highlights the characterization of nanoformulations with respect
to drug loading, bound percentage and hydrodynamic size of the liposome. For the final
assembled liposome nanoformulation, we used Chloroform to Ethanol in 50:50 ratio as
WA is easily soluble in Ethanol.

Table 4.1: Characterization of developed Liposomal Nanoformulation
The developed WA Liposomal NF is stable, non-toxic and shows efficient
drug binding and transmigration across the in-vitro 3D BBB trans-well
model
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4.3.3 Liposomal Nanoformulations are not toxic
To evaluate the in-vitro cytotoxicity of the developed WA-LNF, we performed Trypan
blue cell viability assay from the collected SHAPP cells treated with various
concentrations WA-LNF. Our cell viability studies show that the Blank and drug loaded
liposomes did not cause cytotoxicity, as the percentage of viable cells, were similar to
untreated control up to 48 hrs of treatment. They did not obstruct the cell viability and
did not cause any toxicity to the cell cultures (Figure 4.5). Thus, signifying that all the
tested doses of liposome NF were nontoxic and developed NF will not have any
biocompatibility issues as the liposomes are made of biocompatible constituents.

Figure 4.5 Cell viability test
The trypan blue viability test showed that the prepared liposomal nanoformulation
were not having any effect on cell viability
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4.3.4 Liposomal Nanoformulations transmigrate across the BBB
The developed WA-LNF were added to the in-vitro BBB 3D model on the apical side of
the trans-well. This setup was then incubated for 24 hours, TEER values were
measured to insure that the WA-LNFs did not harm or distort the membrane integrity.
FITC Dextran studies show that the % of transmigration was approximately 45% after
the WA-LNF treatment. This ensured that the WA-LNF was able to transmigrate through
the BBB (Figure 4.6).
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Figure 4.6 In-vitro WA Liposome transmigration and effect on BBB
integrity compared to control

4.3.5 Functional Efficacy of the WA-LNF upon BBB transmigration (ELISA)
The efficacy analysis of the WA-LNF with respect to the cellular uptake and functional
efficacy was performed. As explained before, the basal side of the BBB had SHAPP cells
grown to full confluency. The SHAPP cells were harvested from the basal side of the
transwells, the supernatant was collected after 24 hours of WA-LNF treatment. Control
wells were treated by PBS. Supernatant were then analyzed by Human Aβ40 ELISA kit
and compared to control. The standard curve was generated by utilizing different
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standards (different concentrations) and was utilized to calculate the concentration of
Aβ40 in the sample supernatant. We observed approximately 40% reduction in the
secreted Aβ40 levels in the WA-LNF treated cell cultures compared to untreated control
(Figure 4.7)

Figure 4.7 Effect of Liposomal WA across the BBB
WA-LNF decrease the Aβ40 levels across the BBB in the SH-APP cells,
compared to untreated BBB associated SHAPP cells

4.3.6 WA release study by membrane dialysis method
Here we show a release pattern of the hydrophobic drug WA from liposomal
Nanoformulation. The liposomes prepared were loaded with 100mg/ml WA initially, and
upon analyzing the unbound drug, we found that the drug bound to the liposomes was
~29% (29mg/ml). Upon performing the membrane dialysis experiment with the drugloaded liposomes, we demonstrate that the cumulative release of WA was found to be
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29.73µg/ml until 24 hours. In this study, the surge of WA release was observed between
1-2 hours of the release, where a maximum of 4.5mg/ml drug release was observed.
Further, show that our liposomal nanocarrier displays a prolonged release pattern of
2+/1mg/ml of WA until 48 hours (Figure 4.8).

Fig 4.8 Drug release profile of WA
A) The graph demonstrates the concentration of WA release over the time of 48
hours. The surge of drug release was observed between 1-2 hours and later a
prolonged release until 48 hours was observed. B) Cumulative drug release until
48 hrs.
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This design of liposomal delivery system for the hydrophobic drug molecule WA is
promising as it has improved the encapsulation efficiency and enriched the drug retention
time within the liposome. Therefore, it becomes utmost necessary to validate the release
studies of WA from the liposome and the factors leading the encapsulation and retention/
release of WA. This membrane dialysis experiment shows an effective way of and release
method using dynamic dialysis to study the liposomal membrane permeability of
hydrophobic compounds.

4.4 Discussion
In-vitro cell culture based studies, ex-vivo studies and clinical studies with respect to AD
or AD-like neurological diseases indicate towards the heavy load of Aβ deposition in the
aged patients [292-295]. Amyloid deposition during disease progression covers almost the
entire brain [296-299]. Aβ plaques are reported to be heavily toxic to the CNS cells. The
neuronal cells lose their communications, undergo oxidative stress and eventually lose
their functions contributing towards disease pathogenesis. Therefore, targeting Aβ in the
brain could be of significant therapeutic advantage. The major shortcoming pertaining to
CNS targeting drugs is the BBB, which restricts the transport of most of the potential and
vital drugs. Considering this problem, nanotechnology shows a promising potential in
delivering drugs and targeting specific regions in the brain [109, 300, 301]. The field of
nanotechnology is gaining more attention and is able to address more drug delivery and
drug targeting challenges. The major attributes of nanomaterials and their conjugates like
magnetic nanoparticles, magnetic-electronanoparticles, metallic nanomaterials, gold and
silver nanoparticles, polymeric nanomaterials, metal-polymer nanocomposites, nanotubes
etc. is their small size (in the range of nanometers). The inciting growth and clinical
adoption of nanotechnology in the field of medicine is termed as nanomedicine. The
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important elements of nanotechnology are the minute size range, significant measurement
and transformation at nanoscale and nanoscale specific functions over micro and bulk
drug particles. The development of nanomedicine to the succession into clinical stage is
very sensitive and complex process. Extreme preciseness and expertise is required to
synthesize and characterize the developed nanoparticles, then studying its functional
efficacy in-vitro and in-vivo, preclinical studies in non-human primates and then finally
clinical trials. The nanomedicine or nanoparticles against diseases can be broadly
categorized into (i) Polymer and liposome nanomedicine [302] and (ii) metal based
nanomedicine [303-305]. Nanomedicine or nanotherapeutics is utilized against imbalance
and abnormal disease factors in neurological disorders. Nanomedicine could be used for
disease diagnostics as well as against neuropathological diseases, promotion of
functional regeneration of damaged neurons, provide neuroprotection and facilitate drug
delivery across the BBB.

Our laboratory is working in the field of nanomedicine delivery against infectious disease
from several years and has demonstrated that anti-HIV drug loaded magnetic nanoparticle
under the influence of external magnetic field can transport the anti-HIV drug across the
BBB and can achieve the desired antiviral efficacy without inducing any cytotoxicity [108,
287, 288, 306]. The need of nanotechnological intervention in the field of drug
development and delivery is extremely pressing in the current scenario. With the advent
of various nanotechnological methods.

In this project, we have focused towards organic nanomaterials based medicine carriers
i.e. liposomes to emphasize their advantages in context of therapeutics. Development of
liposomes was intended primarily towards therapeutics and major attention was given
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towards their controlled size, stability, drug entrapment efficacy and sustained drug
release [307]. The rationale behind utilizing liposomes in this study was to exploit the
advantage of liposomal neuronal cells entry through the endocytic pathway [308-310]. We
have employed liposomes as our drug delivery vectors due to the major qualities of the
Liposomes. Liposomes are lipid bi-layered entities [311-313] and have an advantage over
other nanoparticles as they can be loaded with both hydrophobic and hydrophilic drugs.
The lipid bilayer of the liposomes captures the hydrophobic drug molecules. The
liposomes are made up of biocompatible constituents like lipids and cholesterol. In this
study, we are studying a novel formulation of phospholipid-based liposomes, which are
made of egg α-phosphatidylcholine (amphiphilic molecule having a hydrophilic head and
two hydrophobic polar chains) which is highly biocompatible, adaptable, stable, and forms
bi-layered membranes when dispersed in aqueous or saline environment. Cholesterol, the
second important constituent of developed liposomes, can facilitate the preferential transit
of liposomal carrier through BBB and can be easily taken up by neuroblastoma cells.
Liposomes are ideal drug carrier systems as their morphology is comparable to the cellular
membranes, plus they can incorporate major variety of drugs.

Moreover, since various nanoparticles have large surface areas and have potential for
drug delivery, the challenge arises during efficient loading of hydrophobic drugs, or high
amounts of combination drugs on a single nanoparticle. Liposomes are promising, as
loading hydrophobic drugs as well as combination drugs is easier and efficient in
liposomes due to their hydrophobic as well as hydrophilic components. The liposomes can
enter the cells in three ways, firstly they can be adsorbed by cell membrane and then
lipase enzymes degrade their lipid bilayers and the active drug molecules are released
and are diffused in cell membrane as well as cytoplasm. Secondly, liposomal membrane
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can directly fuse with the cell plasma membrane, releasing drugs into cytoplasm, and
thirdly via receptor mediated endocytosis.

In this study, we were able to encapsulate the hydrophobic drug WA in the liposomes by
dehydration method. Our results in this study demonstrate that WA-LNF had a
hydrodynamic size of ~450nm in size and showed 28% drug binding capacity, with no
cellular toxicity. The charge carried by the developed liposome was positive, therefore
there was no aggregation of liposomes and due to positive ζ-potential, and it was easier
for the liposomes to interact with the cells. We also studied the BBB integrity by measuring
the TEER and paracellular permeability using FITC-dextran transmigration of the
developed NF. We demonstrated that the developed WA-LNF showed almost 50%
transmigration across the BBB and did not disrupt the integrity of the 3D in-vitro BBB
model. Next, we wanted to analyze the efficacy by which the liposomes entrap the drug
and the continuous and sustained release of WA from the liposomal complex into the
release medium. Our membrane dialysis study showed that the drugs start releasing from
the liposomal complex within couple of hours and the dug release is continuous and
stable. These liposomes cross the BBB either by absorptive-mediated transcytosis or
receptor-mediated transcytosis, facilitated by the electrostatic communication between
liposomal positive (cationic) charge and endothelial cells membrane’s negative (anionic)
charge [314]. WA liposomes could be of promising therapeutic importance. Therefore, in
order to take this developed NF to further clinical levels, several optimization studies
regarding the stability and toxicity plus efficient BBB transmigration, are needed. These
liposomal nanoparticles are promising in applications such as age related or
neuropathological diseases, which require the delivery of the drug across the blood brain
barrier. The drugs available towards neurological issues are rejected due to
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pharmacotherapy failures like inadequate physical chemistry, minimal absorption,
unfavorable pharmacokinetic parameters, instability and toxicity. This urges the need of
the alternate medicine/nanomedicine. Further in vivo efficacy and drug delivery
mechanistic studies are necessary to explore WA’s therapeutic role in neurological
disorders like HIV associated neurocognitive disorders and AD. Therefore, the WA
Liposomal synthesized in our study have the potential of a combined therapy as a
neuroprotectant and anti-inflammation molecule. It requires further studies to explore more
in this field.

98

CHAPTER 5: MOLECULAR BASIS FOR MID-REGION Aβ CAPTURE BY LEADING
ALZHEIMER’S DISEASE IMMUNOTHERAPIES: MECHANISM STUDIES

5.1 Introduction
There is a constant speculation and scientific discrepancy behind the selection of main
disease mechanism or the causal factor of AD but the amyloid hypothesis is the most
important and accepted one. In the amyloid hypothesis, AD is caused by excessive
accumulation of the Aβ peptide leading to the plaques. Amyloidogenesis has been
associated with a broad spectrum of diseases in which amyloid protein is invariably
misfolded and deposited [1] [315, 316] [317]. The monomers react with neurotoxic
oilgomers and aggregate into multimers, fibrils and finally fibrillary aggregates (Figure 5.1).
The multiple structural forms of Aβ interact and associate together forming big and
insoluble plaques. Therefore, in order to understand and evaluate the ability of WA
chemical structure to physically interact with Aβ protein structure (monomeric and
multimeric), in this chapter, we have focused on the physical interactions of Aβ with WA
to understand the mechanism of WA working in the disease pathway.

99

Figure 5.1 The stages of amyloid fibril formation and the associated
cellular toxicity

Before studying the interaction of Aβ directly with WA, we focused on elucidating the role
of WA and its effect on the enzymes involved in Aβ processing, i.e. β and γ secretases.
These enzymes are extremely important in APP processing during amyloidogenesis, to
release Aβ that is why we speculated that WA might have a direct effect on these enzymes
as well. We designed an experimental study to have a deeper understanding towards
mechanism of action of WA by measuring its effect on β and γ secretases. Even though
we were able to demonstrate the role of WA in decreasing the secreted Aβ in our
preliminary in-vitro study, we were not able to observe effect of WA on β and γ secretases
enzymes. This could be due to low amounts these enzymes secreted by the SHAPP cells,
which went undetectable by the ELISA technique. We plan to do in-vivo and in-silico
studies to address this question. Therefore, in this thesis currently, we hypothesize that
that the main target of WA is Aβ monomers and aggregates, and WA may be highly
interactive with the specific regions of Aβ proteins, for which we further performed in-silico
studies to support our hypothesis.
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Aβ peptide is a sticky peptide which is abundant in the brain plaques, and its abnormal
accumulation of Aβ in CSF and plasma [19, 318] result due to biochemical abnormalities
caused by APP mutations [292]. This concept has been well reported by study
incorporating 3D human neural cell culture model to demonstrate Aβ accumulation [319].

There are various strategies studied by researchers globally, where the popular approach
towards AD is the targeting strategy of the various antibodies being developed as
immunotherapies. Antibodies are considered amongst the most promising approaches for
the treatment and prevention of AD and AD related diseases. The promising Solanezumab
(Eli Lilly) and crenezumab (Genentech) were humanized monoclonal antibodies targeting
the mid-region of the neurotoxic Aβ peptide [320] an early biomarker of AD pathology and
the major component of plaques found in AD-affected brain. Results of large-scale phaseIII clinical trials of solanezumab, and clinical anti-Aβ antibody called bapineuzumab
(Pfizer, Johnson & Johnson) in patients with mild to moderate AD were reported in 2014.
Both studies concluded that treatment did not improve clinical outcomes in AD patients.

Unlike solanezumab, bapineuzumab demonstrated target engagement in ApoE4 carriers,
lowering brain amyloid and hyperphosphorylated-tau (the constituent of tangles) and total
tau levels in cerebral spinal fluid relative to placebo [321]. The failure of bapineuzumab
and solanezumab to improve clinical outcomes is considered by many to be a question of
treatment window since deposition of amyloid in the brain can predate symptomatic
dementia by decades [322]. Thus, clinical trials examining anti-Ab antibody treatment in
at-risk, asymptomatic individuals are planned or underway. These include the antibodies
solanezumab (in the Anti-Amyloid treatment in Asymptomatic Alzheimer’s disease (A4)
trial [323] in the Dominantly Inherited Alzheimer Network (DIAN) trial [324]), crenezumab
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(in

the

Alzheimer

Prevention

Initiative

(API)

trial

[325])

and

gantenerumab

(Chugai/Hoffmann-La Roche – in the DIAN trial).

The murine parent antibody of the humanized monoclonal antibody solanezumab, 266 is
reported to target Aβ within residues 13–28. It becomes important to understand Aβ
engagement with the clinical candidates for facilitating the development of active Aβdirected therapies that can be drug therapy (naturally acquired plant based drugs like ASH
and Curcumin) or it can be immunotherapy (vaccines). Studies demonstrating the
involvement of mid region of Aβ employed crystallized recombinant solanezumab Fab
fragment complexed to the mid-region of the Ab peptide and determined its structure to a
resolution of 2.4 A˚[326]. This study showed the conformation adopted by the Ab peptide
in the antibody-binding site. They observed unambiguous electron density across Aβ
residues 16–26 (KLVFFAEDVGS) in the most complete model of solanezumab.

Earlier, anti-N-terminal antibody holding Aβ in an extended coil over the first eight residues
were reported [327-330] Antibody like bapineuzumab and its murine parent 3D6, showed
the N-terminal five residues of Aβ captured [331]. Additionally, ponezumab (Pfizer)
antibody with specificity for the C-terminus of Aβ40, was demonstrated to attach to the
highly hydrophobic region in an extended coil conformation [332]. The structural studies
of anti-Aβ structures, provides a foundation for the designing of upcoming and next
generation immunotherapies to lower cross-reactions and more interaction with the
peptides. The understanding of peptide or protein structures may also help in the
identification of alternative mechanisms of action of immunotherapies or drug therapies,
by exploiting the proteins sharing elements of the Aβ epitope.
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The majority of patients with AD suffer from impaired cerebral circulation. Aβ multimerizes
and interacts with Aβ fibrils and Aβ oligomers act as seed to further accumulate the fibrils
into multimers and clump, forming clearance-resistant abnormal aggregates or plaques.
Since immunotherapy candidates like solanezumab, and crenezumab failed the clinical
trials. It becomes imperative to unfold and dig new tangents of therapy. The natural
components derived from the plants and plant products become important candidates in
targeting Aβ during AD pathogenesis. Therefore, we chose as a neuroprotectant and
studied its interaction with the middle region of Aβ, like Immunotherapy candidates like
solanezumab. Current advances in bioinformatics and drug development made it easier
for us to strategize the in-silico experiments. Upon understanding the Aβ hypothesis and
we were interested in understanding the targeting mechanisms of the WA drugs against
Aβ. We assessed WA’s interaction with the peptide and focused on analyzing the targeting
specificity to strengthen the importance of WA as a promising drug candidate against the
Aβ fibrils and their aggregated complex and insoluble structure.

The in-silico molecular dynamics structural studies capable of designing protein 3D
models and estimating drug binding with the antigens or the protein of interest is currently
one of the most desirable techniques. In the field of drug discovery and targeting, the
method of finding the best-suited drug to aim at target protein is termed as molecular
fishing (Figure 5.2). There are experimental methods of direct molecular fishing developed
for identification of potential partners of protein–protein and protein–peptide interactions.
The experiments are based on surface plasmon resonance technology (SPR) studies of
the molecules, size exclusion and affinity chromatography techniques and identification of
proteins by employing mass spectrometry (LC-MS/MS). However, in this project there
was no requirement of the molecular fishing as we already have established the role
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of WA against Aβ and we performed in-silico molecular simulation to support our
results and elucidate the mechanism involved.

Figure 5.2 Molecular Fishing
The study of deducing best-fit drugs against a target protein or antigen based
on their structural interactions. The drug candidate interacting with the target
utilizing the least energy structural modifications are chosen to be the bestsuited drug molecule against the protein

Further, we have demonstrated the structure of the Aβ42 protein molecule in the water
environment. Every protein exists in a particular environment, and can reach its maximum
stable structure within a medium or an environment like saline or water. Here we
demonstrate that the PDB model when generated and visualized in a water environment
takes proper structure of Aβ42 protein (Figure 5.3).
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Figure 5.3 Molecule in a water environment.
The figure demonstrates the 3D crystal structure of A molecule in water environment

In this study, we investigate the structural details of the Aβ-WA interaction. We identified
the middle region of Aβ42 as the most critical region for the interaction, which can be
targeted by drugs. WA binding to this region may block further aggregation or addition of
new peptides or may break the mature insoluble plaques. Overall, our study elucidates
the Aβ-WA interaction and clarifies the mechanism by which WA binding depletes Aβ
aggregation and further plaque formation. These results may facilitate the effective
therapeutics against plaque aggregation leading to the treatment of neurotoxicity and
cerebrovascular abnormalities in AD.

105

5.2 Materials and methods
5.2.1 Estimation of Protein Structure
The human crystal structure of Monomorphic A42 amyloid Fibrils (PDBIDs: 5KK3) [333]
was retrieved form the Protein Data Bank (PDB) (http://www.rcsb.org). Additionally, A
monomer protein was modelled by Amber Molecular Dynamics Software, Version 14. The
energy minimization of target proteins was conducted by using online tool Sander package
of AMBER14 resolve the stearic clashes from protein structures. By using, 3D structure of
Alzheimer's A Chain A of monomorphic A 42 (5kk3.A.pdb) as a template with an Evalue of 4.3e-16 and a score of 63, we modelled this protein structure.

5.2.2 Candidate Structure
The steroid lactone WA was selected as the drug of interest for present study. The 2D
structure of WA drug was derived from Pubchem Open Chemistry Database the
ACD/ChemSketch tool. (Pubchem ID: 265237). A detailed compound summary of
chemical and physical properties and of WA were retrieved from PubChem database.

5.2.3 Molecular Docking of WA with A42
Further, WA was docked with A42 by Rosetta, a software suite that includes algorithms
for computational modeling and analysis of protein structures. The avenger binding affinity
of WA cluster of 100 decoys in the common binding pocket was calculated to be
approximately -8.12 REU.

5.2.4 Molecular Dynamics Simulation
To investigate the role of WA on destabilization of A fibrils, we performed extensive µSlength all-atom molecular dynamics (MD) simulations using NAMD [334] with Charmm36
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force field [335]. We performed extensive µS-length simulations to investigate the fibril
disruption and growth inhibition by WA. The A fibrils exist in several polymorphs with
different interfacial interactions between protofilaments [336-339]. Because of the different
local arrangements A have potential implications for biological activities [340], therefore,
we have considered different fibrillar structures of both A1-42 (pdb codes 5OQV, 5KK3,
2NAO) and A40 (pdb id 2M4J, 2LMP, 2MVX). To incorporate local fluctuations in fibril
conformations, we implemented a short 100-ns MD simulation for each of these fibril
structures. From each run, about 1,000 conformations were sampled, making a pool of
6,000 A fibril conformations. WA was screened against these sampled A conformations
using AutoDock Vina [341] and custom scripts [342]. About 100 top-ranked WA-A fibril
complexes from the docking results were analyzed to filter and identify consensus bestranked binding poses. About ten complexes thus identified were used to set up MD
simulations.

5.2.5 Protein Structure Visualization and analysis
The generated protein structures from the Docking experiment were complex and
visualized by Chimera X protein structure visualization software, which shows the 3D
structure of the protein and the specific regions of drug binding. This tool provides several
command tools to view the protein structures, their surfaces, and the intra and inter
bonding between protein-protein or protein-drug interactions.

5.3 Results
As we have established in this thesis, that WA has a direct effect on A levels, we wanted
to further investigate the mechanism of underlying process by which WA might be
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interacting with the Amyloid protein. It was important to address the WA binding/interaction
with Aβ42 and the precise region of binding, and structural modification in protein, if any.

5.3.1 Physical and Chemical properties of WA compound
WA is purified compound derived from from root extract of the medicinal plant Withania
Somnifera known for its importance in the field of Ayurveda medicine. WA molecule is a
size-excluded product from parent compound ASH, and is small in size. WA has been
studied well in various fields research and medicine field including cancer and
angiogenesis. In order to utilize WA for the in-silico study, we focused on detailed
characteristics of WA’s physical and chemical properties, which are available at Pubchem
website (Table 5.1)
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Table 5.1 Characteristics of Withaferin A
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5.3.2 Structural studies
Our structural studies showed that WA has the capacity to interact and bind to the
hydrophobic middle region of the Aβ42. This middle region is reported to be interactive by
various other studies, which reported the interaction of clinical immunotherapy agents/
antibodies promising for immunotherapy, with the middle region of Aβ [320, 343] (as
discussed in Section 5.1). Upon docking the neuroprotectant drug WA with the generated
structure of Aβ42, we established that WA binds to the Aβ protein firmly in the middle
region of the protein (Figure 5.4). The drug sits precisely in the hydrophobic pocket of
Aβ42 protein. This interaction of WA with Aβ42 did not distort the chemical structure of
WA, as it maintained the stability of the WA drug. The amino acid motif involved in the
binding with the WA molecule was “VFAEDVGS” which constructs the mid-region Aβ. This
result was fascinating as WA is a hydrophobic drug, we were expecting its obvious
interaction with the hydrophobic part of the protein, to acquire safe hydrophobic
environment, which will not distort its chemical structure. The representative figure of
protein structure complexed with WA shows position of single amino acids (one letter code
labelled) and shows the placement of WA near the FAEDVGS motif (Figure 5.5). Amino
acids in the hydrophobic core are sequenced as VFAEDVGS (F=Phenylalanine, A=
Alanine, E=Glutamic acid, D=Aspartic Acid, V=Valine, G=Glycine, S=Serine). These
amino acids help in facilitating the interaction between protein and drug, leading to potent
protein-drug interactions.
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Figure 5.4 Visualization of protein structure interacting with WA
Visualization of the generated protein drug complex with the help of Chimera X,
visualization software. The pdb file generated by the docking experiment was
uploaded in the ChimeraX software. This figure demonstrates the Mesh view of
the Aβ42 protein (golden ribbon) with WA (Red, Blue and Gold sticks chemical
structure).

Figure 5.5 Visualization of the amino acid labelled protein drug complex
The pdb file generated by the docking experiment was uploaded in the ChimeraX
software. This figure demonstrates the Mesh view of the Aβ42 protein (golden ribbon)
labelled with one-letter amino acid code, and its interaction with Withaferin A (Red, Blue
and
Gold
sticks
chemical
structure).
(Sequence:DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA
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5.3.3 Aβ has an interactive hydrophobic motif
Upon deriving, the interaction site of WA with the hydrophobic middle region of the protein
(Figure 5.6) and labeling the amino acids in the hydrophobic core sequenced as
VFAEDVGS. The figure demonstrates the mesh view of the Aβ42 protein (golden ribbon)
labelled with one-letter amino acid code, and the highlighted (Teal) mid-region of the
protein. It shows the interaction of WA (Red, Blue and Gold sticks chemical structure) with
the mid- region (Teal) (hydrophobic pocket) of the Aβ42 protein. It is a clear representation
of protein-drug interaction. Aβ capture by the neuroprotective agent is explained here with
the reported mid-region Aβ-WA complex of the generated drug-protein in-silico structure.
Additionally, the protein surface view presentation (Figure 5.7) shows that WA interacts
with the hydrophobic pocket which has minimal stearic hindrance. The minimal stearic
hindrance provides a potent area or a sort of pocket for WA to bind, without loosing its
benzene rings, or getting distorted. Visualization of the generated protein drug complex
with the help of Chimera X visualization software, demonstrates the surface view of the
Aβ42 protein (golden ribbon) labelled with one-letter amino acid code, and its interaction
with WA (Red, Blue and Gold sticks chemical structure). WA interacts with the mid- region
(Orange arrows) (hydrophobic pocket) of the Aβ42 protein.
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Figure 5.6 Mesh view of the Aβ42 protein (golden ribbon) and its interaction with
WA
Red, Blue and Gold sticks represent the WA chemical structure and the highlighted
Teal colored section shows the hydrophobic middle region of the Aβ42 protein, which
contains FAEDVGS motif

Figure 5.7 Surface view of the Aβ42 protein (golden ribbon) and its
interaction with WA Red and Gold sticks represent WA and show its interaction
with the mid- region (Orange arrows) (hydrophobic pocket) of the golden surface
of Aβ42 protein
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5.3.4 Drug-protein interactions via Hydrogen bonding and the binding is stable and
specific
Furthermore, we wanted to study the type of bonding if any between these two moieties.
Upon selecting the probable hydrogen bonds by the Chimera software interface, made
between drug and protein, we were able to show the presence of 3 significant Hydrogen
bonds made by WA with Aβ42. The best-docked energy complexes were further deep
analyzed based on hydrogen and hydrophobic interactions pattern between ligand and
target protein. The active binding region of Aβ was hypothesized to be the middle region
based on literature involving immunotherapies and their interaction with amyloid peptides.
Focusing on the hypothesis when we ran our experiments, our results proved our
hypothesis and showed that WA binds within the active region of target protein by forming
couple of hydrogen bonds. Figure 5.8 A,B demonstrate the closer look of the mid region
of Aβ42 protein and show three specific hydrogen bond interaction of WA with the amino
acids ASN17, GLY15 and SER16 of the protein, from a slightly different angle. The
structure activity relationship (SAR) analysis shows that WA forms three hydrogen bonds
at specific residues (ASN17, GLY15 and SER16) with target protein. The OH- (anions)
(hydroxyl group) had a strong interaction with the H+ (cations) of the three amino acids
namely ASN17, GLY15and SER16 (Figure 5.8 A, B) These interacting residues Asn
(C4H8N2O3), Gly(C2H5NO2) and Ser (C3H7NO3) have molar masses of 131.12g/mol,
75.07 g/mol and 105.09 g/mol respectively. They are studied to be significant in the
downstream signaling pathways.

114

Figure 5.8 Demonstration of Hydrogen bonding between Aβ42 and WA
A) Three Hydrogen bonds are formed between WA and the Aβ (Yellow lines) giving
stability to the binding structures, B) The figure in the zoomed-in area of the mid
region of Aβ42 protein and shows three specific hydrogen bond interaction of WA
with the amino acids ASN17, GLY15 and SER16 of the protein.
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5.3.5 Dynamic modelling: Speculating the mechanism of action of WA
Our preliminary computational work on WA binding to A fibril has shown that WA binds
in two physiologically relevant sites and affects the fibril growth and stability. Specifically,
WA can successfully recognize and insert through the loop segment between residues
24-33 in the A fibril. This insertion of WA into the A fibril destabilizes the fibril, suggesting
that it can potentially destabilize the fibrillar structures. Another binding site is on the fibril
interface and this can potentially inhibit the fibril growth. We will perform extensive µSlength simulations to investigate the fibril disruption and growth inhibition by WA (Figure
5.9).

Figure 5.9 Two proposed mechanisms of WA’s interaction with A42 fibrils
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5.3.6 Protein drug binding is stable and specific with time lapse
Upon the time-lapse study of the interaction of two representative WA molecules with the
matured fibrils of Aβ42, we report constant movement of WA between the fibrils and then
eventually settling down in the middle portion of the proteins, behaving similar to what we
showed in our monomer structure depiction studies (Figure 5.10).

Figure 5.10 WA interaction with A42 is stable
These structures are the stills from the time-lapse video of interaction of WA
molecules with A42 protein, which shows that WA remains interacting with
the protein for a longer duration, and with stability

5.4 Discussion
In the era of increasing neuropathological issues and complexities and lack of efficient
drug targets, it becomes important to understand the structure and function of the target
disease causing protein to generate the minimal free energy structures and identify the
most potent target in-silico before attempting the in-vivo or clinical attempts of testing the
drug efficacy. The advantage of in-silico study is that it gives us an opportunity to explore
thousands of drug candidates and study their interaction with the target proteins, enzymes
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or receptors, virtually in a saline or water environment. In-silico study are extremely
efficient, accurate and financially minimal, and saves valuable time of the researchers.
The experiments deliver top 5 or 10 minimal free energy protein structures and potent
drug candidates to initiate the studies, giving ample opportunities to the researchers to
design experiments, elucidate drug targets, mechanisms and risk before testing them invitro or in-vivo. Computational interpretation or simulation of drug candidates or molecular
compounds and demonstrating their binding analysis in the active region of target proteins
opens pharmaceutical opportunities and the chance for the research laboratories to test
the efficacy of drugs [344]. In this project, as shown in Chapter 2, WA is capable in
decreasing the toxic effects of secreted A40. Upon establishing that WA has
neuroprotective properties, we wanted to elucidate the mechanism underlying behind the
neuroprotective action of WA. Therefore, we were interested in molecular simulation
studies to support our hypothesis of WA interaction with A structure, resulting in
morphological changes in the protein aggregates, which may prevent the further insoluble
aggregation of A into plaques. In our in-silico approach, we have tested WA against AD
pathogenesis and after employing multiple online drug analysis computational tools and
servers to predict the efficacy of WA compound, we showed WA as a potent compound
against A induced AD pathogenesis.

In this chapter, we examined the structure of Aβ and studied its interaction with the
neuroprotectant WA. There are multiple forms of amyloid, from single Aβ peptide to
interacting monomers, which further aggregate into multimers, protofibrils and then into
mature fibrils. These mature fibrils aggregate with the help of seed oligomers, into
insoluble aggregates of A plaques. Our drug candidate WA targets on A by two possible
mechanisms. First, it interacts with single fibers and does not allow the fibrils to mature
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retaining their morphology and secondly it inhibits the aggregation, thereby reducing or
inhibiting plaque formation (Figure 5.11). These results are important as therapeutic
strategies as they show promising towards targeting amyloidogenesis has been
associated with multiple and extensive range of neurological diseases. In AD specifically,
abnormally misfolded amyloid is escaping immune clearance and their deposits in cells
leads to conditions like memory loss, dementia and motor deficits [345].

Figure 5.11 Working hypothesis of mechanism of WA

Our molecular simulation studied demonstrate that WA perfectly binds with the middle
region of Aβ42 protein by forming 3 distinct and stable hydrogen bonds. The mid region
of Aβ42 protein shows interaction and formation of hydrogen bonds between WA structure
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and specific amino acids ASN17, GLY15 and SER16 of the Aβ42 protein. Our preliminary
computational study on WA binding to A fibril has shown that WA binds in two
physiologically relevant sites on A which are loop segment of the protein and the fibril
interface, which affects both fibril growth and fibril stability. Aβ is one of the important
player leading to plaque formation is of important therapeutic concern and WA binds to
the hydrophobic motif of amyloid beta and the binding is specific and stable, and is one
step towards AD therapeutics. Many further studies are definitely required in this field to
explain dynamic modelling interactions, stable environment, aggregated fibrillary toxicity,
water coefficient, angle of the Hydrogen bonds and the bond strength. It is also important
to run simulation for longer durations to ensure the stability of WA molecules in the amyloid
complex, to avoid re-integration of the aggregates in the diseased scenario.

Our future in-silico studies will be focused on studying interaction of β-secretases with
WA, to analyze if β-secretases can be potent therapeutic target for AD treatment or not. A
variety of BACE1 inhibitors with promising properties have been identified with structurebased drug design strategies, leading to clinical development of selected inhibitors.
Despite the clinical potential exhibited by several inhibitors, an effective FDA approved
BACE1 inhibitor is still lacking. Therefore, we will investigate the role of WA as a potential
BACE1 inhibitor. Several x-ray crystal structures of BACE1 with or without inhibitors are
available (e.g. pdb id: 1FKN, 3DM6, 3KYR, 2G94, 2VKM, 1XS7), showing slight
conformational variability in BACE1-compound complexes. Therefore, we will generate
diverse array of conformations by performing >100 ns MD simulations of BACE1 and
sample about 1,000 conformations for docking/screening with WA. About top five WAbound complexes will be selected for performing MD simulations to examine the stability
of the complex. Due to the similarity of the active site binding pockets in BACE1 and
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BACE2, selectivity of the BACE1 inhibitor can be limited. To differentiate the binding of
WA between BACE1 and BACE2, we will perform similar screening analysis of WA against
conformations of BACE2. The top-scoring binding poses that are different in WA-BACE1
compared to WA-BACE2 will be selected for further MD simulations.
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CHAPTER 6: FINAL CONCLUSIONS AND FUTURE DIRECTIONS
Parts of this chapter appear in the journal Biosensors & Bioelectronics. Published online
2016 Jun15. doi: 10.1016/j.bios.2016.01.065.

AD is described as the progressive and irreversible neurodegenerative disorder,
characterized by the presence of abnormal extracellular and insoluble Aβ peptide ([346348] which aggregate into neuritic plaques [349-351]. Aβ protein deposition in the human
brain is one of the key component in possible theories of the AD pathogenesis [292]. The
presence of hyperphosphorylated tau protein in the brain resulting in the formation of NFTs
is reported [352, 353]. Other theories propose the role of the APOE ϵ4 allele [354] which
may pose as a risk factor in AD pathogenesis [355, 356]. The continuous accumulation of
the plaques and tangles in the brain result into toxicity leading to cognitive impairments
[357]. Aβ is produced from a transmembrane APP through abnormal cleavage by the β
and γ secretases [14, 318]. Aβ proteins can occur in soluble and fibrillary forms, and the
senile plaque which are typical in AD pathogenesis are aberrant plaques which are dense
and insoluble comprised of Aβ fibrils and toxic oligomers [358]. Furthermore, Aβ
production triggers abnormal Tau processing, linking Aβ accumulation and tau protein
phosphorylation [359] which are also believed to be an important contributor in AD
pathogenesis. NFTS are constitutive of Tau which is a microtubule-associated protein and
in diseased scenario Tau phosphorylates and leads to distortion in the microtubular
conformations, implicating towards in the pathological progression of AD [360]. There are
varied opinions towards the pathological features behind AD mechanism, and amongst
them Aβ hypothesis is the most accepted one, associated with the onset and progression
of AD. Aβ is found in two main isoforms (amino acid chain length are different); namely
Aβ40 and Aβ42 [361, 362] where Aβ42 is more toxic but less abundant compared to Aβ40
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which is reported in high concentrations in the AD brain. These peptides undergo self and
spontaneous association leading to supramolecular aggregated assemblies of dense and
insoluble. Plaque formation leads to deteriorated neuronal synapses and communication,
therefore producing more neurotoxicity. The Aβ aggregation leads to release of ROS and
NO, contributing to neurotoxicity, altering immunological responses, boosting abnormal
secretion of pro-inflammatory cytokines, formation of soluble neurotoxic oligomers and
aggregating fibrils leading to severe neuropathological conditions, contributing towards
poor neuronal communications, memory deficits, motor disorientations and dementia. The
Aβ oligomers attach with the neuronal lipid bilayer and induce abnormal alterations,
depolarization, Ca ion up-regulation and increase in ROS levels [363]. In our future
studies, we intend to study the effect of WA on the Ca ions regulation and function which
will give us better insight into WA action mechanism as these Aβ associated
neurodegenerative pathological changes damage the neuronal network by altering
synaptic structure and functionality resulting in the spatial memory weakening linked with
neuronal dysfunctions.

We also want to study the effect of WA on the mitochondrial dysfunctions caused by Aβ
load as a result of altered energy homeostasis and insulin signaling pathways. Most
deteriorating Aβ neurotoxic mechanisms comprise oxidative stress and mitochondrial
damage. It has been reported that the perivascular accumulation of Aβ harms the BBB,
including microbleedings, damaged neuronal network, and abnormal inflammatory
reactions [364]. Therefore, in our future studies we want to study WA as the endothelial
protective drug by lowering oxidative damage and vascular dysfunction, favoring healthy
BBB.
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As a response to abnormal concentrations of Aβ plaques and NFTs aggregation,
microglial infiltration at the site has been reported which plays a vital role in triggering
innate immune response against the aggregation. Additionally, the increase in release of
inflammatory cytokines attracts microglia towards the plaque-populated regions, therefore
worsening the situation and contributing towards intense neuro-inflammation [365-369].
The link between microglia and AD is well studied and it has been reported that microglia
tend to accumulate near the senile plaques in the AD brain [370]. Aβ aggregation induce
microglial infiltration and induce neuroinflammation by binding with microglial innate
immune receptors (G-Protein-Coupled Receptors), which initiate an inflammatory cascade
[371]. In AD, synaptic impairment and associated neuronal death prompted by Aβ peptide
are in part due to microglial and astrocyte cells activation. Microglial activation results in
pro-inflammatory cytokines and ROS production towards chronic inflammatory process.
Additionally, astrocytes are involved with neuroinflammation, too, and are activated by Aβ
load, pathogens, and oxidative stress, producing inflammatory cytokines cyclooxygenase2 enzyme, augmenting Aβ production [366, 372, 373].

Several studies indicate towards some correlations of Aβ to decreased memory scores
[374, 375] and difficulty of patients to perform memory tasks [293, 376]. Therefore, in our
understanding it becomes utmost important to study the effect of drugs which can target
Aβ without causing cytotoxicity in neuronal cells. Therefore, in this study we introduced
WA, and explored its potential in decreasing Aβ. WA is a purified steroidal lactone, derived
from the parent component Ashwagandha (from W. Somnifera). Our previous study has
shown that the most evident and abundant component of ASH are Withanolides, and WA
is an active moiety of Withanolides with significant Aβ decreasing properties [119].
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In the current study, we demonstrated the neuroprotective role of WA against Aβ40
toxicity. We have also shown that Aβ40 associated toxicity is boosted by the presence of
HIV-1 Tat and drug of abuse Cocaine in-vitro. We have shown that WA is able to reduce
the A Aβ levels induced by HIV-1 Tat and Cocaine. WA reduces associated neurotoxicity
and boosts synaptic plasticity and neuronal communications, by promoting synaptic
plasticity associated gene expression and aiding in dendritic length and communication in
cultured neurons, which we have discussed in Chapter 2.

In case of amyloidogenic diseased pathway the APP protein is abnormally cleaved by γ
and β secretases leading to the production of Aβ peptides [247], which then aggregate
and form insoluble plaques [35, 377-379]. Therefore, we wanted to look at the mechanism
by which WA could be working. Upon performing γ and β secretases targeting ELISAs,
from the WA treated cell supernatants, we found that WA showed no effect on the levels
of γ secretases. Additionally, we also wanted to look at the effect of WA on the β
secretases, but we were not able to detect differences in β secretases by the in-vitro
ELISA studies, which may be due to undetectable amount of β secretases in the SHAPP
in-vitro cell cultures. This definitely requires future in-vivo studies where we can work with
APP/PS1 mice models to learn more about the effect of WA on β secretases, if any. Even
though, cohesive studies including systematic Aβ clearance by targeting mechanism and
related molecules are scarce, we believe that γ and β secretases may be potential drug
targets. We believe that targeting AD should not only be approached by targeting Aβ only
in CNS, but targeting signaling enzymes and factors may be impotent therapeutic
approach as well.
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In continuation to the effect of WA on Aβ, we also wanted to venture in the field of Aβ
associated inflammation, and effect of W on inflammation, if any. As discussed in Chapter
3, inflammation is one of the associated atrocities during Aβ associated neurotoxicity, and
there is a need of drug or combination of drugs to target inflammation. In order to address
the inflammation due to Aβ accumulation, we have shown that WA inhibits NF-κB
associated neuroinflammation, as Our NF-κB assay showed that WA was able to inhibit
the expression of NF-κB2 and down-regulated RELA transcription factors, which plays a
major role in the expression of inflammatory chemokines and cytokines. Our second drug
of interest CRID3 was shown to downregulate various chemokines like C5, CCL20,
CCL26, CCL5 and receptors like CCR6 and CXCR2. Additionally, CRID3 targets IL1-β by
reducing the levels of Caspase-1 enzyme, which converts pro- IL1-β to active e IL1-β.
These results are very important to target inflammation during Aβ neurotoxicity and
microglial infiltration. In summary, our study highlights the mechanism by which WA
modifies and inhibits NF-κB activity. We also show the role of CRID3 in targeting
inflammasome activation as it targets IL-1β and down-regulation of IL-1β could be of
potential importance in targeting inflammasome activation. Future studies can focus more
on studying the effect of WA and CRID3 individually at major cytokines associated with
inflammation at gene and protein expression levels. This will give us a clear insight on the
targets of WA and CRID3 in inflammation, which could be of immense therapeutic
potential against Aβ induced inflammation in AD or AD- like diseases.

Having learnt the importance of WA against Aβ induced neuronal toxicity and antiinflammatory role, the next question that we needed to address was the availability of
hydrophobic WA across the BBB into the CNS. The BBB is a structural and
functional obstruction between the CNS and the peripheral, it maintains the CNS milieu
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that is necessary for neural function. It consists of network of endothelial cells, pericytes,
and astrocytes packed together forming Tight Junctions, which regulates minimal
transmigration of molecules from the blood side to the brain across the BBB [380]. The
major issue in targeting drugs to CNS is the presence of BBB, therefore it is utmost
important to tackle BBB transmigration, without distorting the stability and functionality of
BBB and increasing the drug bioavailability on to the CNS. To overcome the
transmigration shortcoming, nanotechnology has been a promising candidate. Utilizing the
role of nanoparticles as efficient drug carriers, we have utilized liposomes as drug carrier
here as liposomes have an advantage over other nanoparticles. They can be loaded with
both hydrophobic and hydrophilic drugs, because the lipid bilayer of the liposomes
captures the hydrophobic drug molecules, which aid in delivering hydrophobic drugs
efficiently and targeting specific regions in the brain for different CNS disease treatments.
We modelled the 3D in-vitro BBB model utilizing primary human endothelial cells,
astrocytes and pericytes grown on a trans-well insert with a membrane, which mimics the
physiological BBB. This developed BBB has constant and stable TEER and is stable [252,
381]. In Chapter 4 we have shown the development of the WA-loaded liposomes (WALNF), and characterized them for their size and drug binding and transmigration efficiency.
We report that developed WA-LNF had a hydrodynamic size of ~450nm in size and
showed 28% drug binding capacity, with no cellular toxicity. We also studied the BBB
integrity by measuring the trans-endothelial electrical resistance (TEER) and paracellular
permeability using fluorescein isothiocyanate (FITC)-dextran transmigration of the
developed NF and reported that WA-LNF showed almost 50% transmigration and did not
disrupt the integrity of the 3D in-vitro BBB.
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Finally, we wanted to elucidate the basic mechanism of WA’s interaction with the Aβ
protein. Aβ monomer comprises of 40-42 amino acid depending on the isoforms of
amyloid. We were interested in demonstrating the structural conformation of the Aβ
protein, and wanted to study if WA binds or interacts with amyloid protein, and if yes, then
where exactly and with what stability. Our molecular simulation studies demonstrate that
WA perfectly binds with the middle region of Aβ42 protein by forming 3 distinct and stable
hydrogen bonds. The mid region of ab42 protein shows ionic interaction and formation of
hydrogen bonds between WA constituents and specific amino acids ASN17, GLY15 and
SER16 of the Aβ42 protein. Our preliminary computational study on WA binding to Aβ fibril
has shown that WA binds in two physiologically relevant sites on Aβ, which are loop
segment of the protein and the fibril interface, which affects both fibril growth and fibril
stability. Future directions in continuation to this study is Amyloid protein crystal structure
assessment via NMR and Mass spectrometry. Crystallization of pure protein derived from
the brain lysates of animal models, and studying them via Nuclear Magnetic Resonance
studies depicting the structure and binding potential of the protein with the WA drug
candidate will give us more clear understanding of the mechanism of action of WA. We
also want to look at the effect of WA on various isoforms of the Amyloid, as at clinical level,
AD brains have multiple isoforms of amyloids reported.

There are many options for future studies to advance the work presented here [382]. The
entire work presented here is in-vitro as this is preliminary work in this field. Major
advanced studies at in-vivo level are required with respect to study the role of WA against
Alzheimer’s disease. Our focus in future is to design a magneto-liposomal
Nanoformulation towards increasing the efficacy of NFs to higher percentage of drug
loading within the liposome (without increasing overall size of NF), and optimization of
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magnetic treatment (time v/s field strength) for better and longer therapeutic efficacy. We
plan to develop and characterize magneto electric liposomal containing multiple drugs
including WA (anti-amyloid and anti-inflammation), CRID3 (anti-inflammation) & BD1063
(anti-cocaine) and study the cargo’s non-invasive BBB transmigration, controlled release
and therapeutic efficacy in the animal models.

In future, we plan to study the therapeutic efficacy, cytotoxicity and on-demand controlled
release of nanoformulations in a cocaine-injected double transgenic (APP/PS1 and Tat)
HAND mouse model. APP/PS1 and Tat double transgenic mouse model exhibit
remarkable elevation of Aβ production associated with certain behavioral abnormalities as
well as HAND pathology in the brain. The objective of this study will be to validate the
outcome of the pre-screening studies using HAND mouse model and to evaluate the
transmigration of the NFs across the BBB under the influence of an external magnetic
field, on demand controlled release on a.c. magnetic stimulation and study the efficacy of
the developed NFs in APP/PS1- Tat mouse model. We will study therapeutic efficacy,
toxicity and in vivo efficacy of the developed NF and will perform immunohistochemistry
experiments to study Aβ deposition. In addition, we will analyze neurobehavioral aspects
in NF injected animals including changes in locomotor activity, motor strength, ability,
balance, and coordination skills, fear-motivated avoidance, novel object recognition,
spatial learning and memory ability, compared to untreated control mice models by
utilizing neurobehavioral tests like Locomotor Sensitization, Rotarod Test, Fear
Conditioning/Active Avoidance, novel object recognition test and Morris Water Maze.
These experiments will provide us basic understanding about the efficacy of the individual
drugs as well as the NF cargo, and drug targeting, delivery and sustained release. Our
developed nanoformulation will be a potent therapeutic cargo towards combating AD and
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AD-like diseases. We believe that successful delivery of our NF will lead to the inhibition
of Tat and cocaine induced Aβ and associated neuro-inflammation that will result in the
improved neuro-cognitive functions in HIV-infected cocaine abusing and aging patients.
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